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ABSTRACT
This thesis spots the light on the development of a novel multi-functionalized
system for application in tissue engineering and on-demand morphogens delivery. Three
types of materials used in this study are synthetic polymer, biopolymer, and nanomaterials.
Polyethylene glycol (PEG), a synthetic polymer was chosen in this study because of its
high biocompatibility, non-immunogenicity, inert nature, ease of modiﬁcation, and reduces
protein denaturation to provide a wide range of physical and mechanical properties. Here,
PEG is used one time as a hydrogel, linear polyethylene glycol-co-lactide (LPELA), and
another time as peptide-PEG based nanoparticles (PxSPCP). Gelatin, a natural polymer has
been widely used for several biomedical applications because of their suitable
biocompatibility, tunable physical characteristics, closely mimic some essential properties
of the native extracellular matrix (ECM) due to the presence of cell attaching and matrix
metalloproteinase responsive peptide motifs. Meanwhile, the peptide-PEG based
nanoparticles were included to provide hybrid hydrogel systems to form networks with
desired combined properties and characteristics for speciﬁc biological applications. These
properties could promote cell response to release certains growth factors that induce
signaling pathways for cells differentiation. Hence, in this thesis, our goal was to integrate
this multifunctional system to develop an ideal type of biomaterials that can letherage the
tissue engineering and targeted morphogens delivery for various treatment applications.
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CHAPTER 1: BACKGROUND INFORMATION
1.1 Bone Tissue Engineering (BTE)
In recent years, the spotlight increasingly focuses on tissue engineering (TE) as an
alternative technique for bone defect repair and regeneration [1]. Tissue engineering
combines biological elements such as stem cells and growth factors with engineering
principles and synthetic materials in order to regenerate functional tissues [1, 2]. Like other
tissues in the body, bone can repair minor small fractures and disease. However, it was
estimated that more than half a million patients had received bone graft procedures yearly
in the US to facilitate repair of a large bone defect [1, 3]. Current techniques for large bone
defects include autologous or allograft bone transplantations. However, a secondary
operation is required for the implementation of autografts and the risk of disease transfer,
and rejection by the host is associated with allografts [4]. Therefore, there is a demand for
better techniques for patients with large bone defects, and TE offers these bone graft
alternatives.
Three critical features have been suggested to the materials that could substitute
bone grafts and stimulate bone healing: osteogenicity, osteoconductivity, and
osteoinductivity [5-8]. The osteogenic potential of the graft is determined by its cellular
content, especially the number of osteogenic progenitor cells capable of differentiating into
bone-forming cells. Osteoconduction is a physical attribute of a graft that permits it to act
as a scaffold allowing vascular and cellular invasion and proliferation. This
1

osteoconductive graft, subsequently, resorbs over time and is replaced by new bone
formation [5]. Osteoinduction is a molecular level process whereby specific growth factors
stimulate the recruitment of undetermined mesenchymal cells and facilitate their
differentiation into chondrogenic and osteogenic cells [8, 9].
1.2 Bone Structure and Formation
The macrostructure of bone is generally composed of two layers: the external dense,
compact bone, and the internal spongy, trabecular bone. The compact, or cortical bone,
provides mechanical strength and support to the structure. The spongy, or cancellous bone
is highly porous to allow better penetration of the vasculature interwoven between calcified
lattices [10]. The primary source of blood cells and vascular structures in bone is the
marrow which is in the core of cortical bone and the spaces in cancellous bone [11]. There
are two major types of skeletal elements, long and flat bones, formed by the processes of
endochondral and intramembranous ossification, respectively [2]. During endochondral
ossification, mesenchymal stem cells (MSCs) differentiate into so-called bone-forming
cells, chondrocytes, osteoprogenitors, and osteoblasts [12]. The avascular cartilage is
formed, serves as a template, and then the skeletal progenitors are formed from the
invading vasculature and differentiate into osteoblasts, which eventually form new bone
on the cartilage template [13]. Conversely, in intramembranous ossification, MSCs cluster
and directly differentiate into cells of the osteoblast lineage. MSCs accumulate locally,
create an ossification center and secrete an extracellular matrix (ECM) that promotes bone
formation [2, 12]. A functional vasculature is thus vital within the bone regenerative
process, supplying of oxygen, nutrients, and cells, and removing of waste [14]. In the
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absence of a functioning and adequate vasculature network, tissue necrosis and failure of
any implanted graft will eventually happen [15]. This suggests that there is a close
correlation between vascularization and bone formation.
Several studies have shown that endochondral and intramembranous ossification of
bone formation is closely tied to the process of the growth of blood vessels from existing
vessels (angiogenesis) [13, 14, 16-18]. In the endosteum, endothelial progenitor cells form
an osteoblast-vascular niche near osteoprogenitor cells within the bone marrow [19]. Bone
cells secrete pro-angiogenic factors, such as vascular endothelial growth factor (VEGF),
that can stimulate signaling responses in endothelial cells, chondrocytes, osteoblasts and
osteoclasts populations that express VEGF receptors [20, 21]. By contrast, bone endothelial
cells secrete factors that can stimulate chondrocytes and cells of the osteoblast lineage [22,
23]. It was shown that the expression of VEGF in the osteoblast lineage results in enhanced
bone angiogenesis and osteogenesis [24]. VEGF, which is a master regulator of
angiogenesis, plays a significant role in blood vessels’ invasion into the hypertrophic
cartilage where the endothelial cells in the invading vessels express factors that stimulate
osteogenesis [4, 13, 18]. In the adult skeleton, bone morphogenetic proteins (BMPs)
regulate the differentiation of periosteal skeletal progenitors during fracture healing and
also mediates osteoblast formation in the bone marrow microenvironment [25]. BMPs
stimulate angiogenesis by osteoblast-derived vascular endothelial growth factor A [26].
This suggests that osteogenesis and vascularization are coupled by spatiotemporal
regulation of paracrine signaling in which the invading vascular endothelial cells secrete
osteogenic factors to promote MSCs differentiation and bone formation [4].

3

1.3 Growth Factors in BTE
One of the approaches in tissue engineering includes delivery of growth factors to
trigger cellular adhesion, proliferation, and differentiation thus accelerating bone and
cartilage regeneration [27]. The type of growth factor and the target cell, cell density,
receptor type, and other signaling events determine the ultimate biological response [28].
In vivo, bone regeneration involves the interplay between inflammatory cells, vascular
cells, mesenchymal progenitor cells and osteocytes [29-32]. Their response is orchestrated
by a certain set of GFs and cytokines that control cellular proliferation, migration, and
differentiation during bone repair. In the first step of bone healing, inflammatory GFs and
cytokines, including fibroblast growth factor (FGF), interleukin-1 (IL-1), and interleukin6 (IL-6), macrophage colony-stimulating factor (M-CSF) and tumor necrosis factor-α
(TNF-α), are involved in the recruitment of inflammatory cells. As the formation of the
fracture callus occurs, high concentrations of pro-osteogenic factors, such as plateletderived growth factor (PDGF), TGF-β, FGF-1, insulin-like growth factor (IGF), and bone
morphogenic proteins (BMPs), stimulate the commitment of mesenchymal progenitor cells
and their subsequent proliferation and differentiation. Simultaneously, proangiogenic
factors, such as vascular endothelial growth factor (VEGF), FGF, BMPs and TGF-β,
trigger the invasion of endothelial cells (ECs) into the newly formed soft callus reestablishing vascular network connection. Also, the intimate crosstalk between osteoblasts
and ECs is mediated via the release of VEGF by osteoblasts that act on ECs to promote
angiogenesis, and via the release of BMPs by ECs, which lead osteogenic differentiation
[29, 33].
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In vitro, several studies have reported that spatiotemporal and sequential growth
factors release may lead to enhance tissue regeneration by providing release profiles and
spatial gradients that emulate the natural healing response [34-36]. On the one hand,
osteogenic growth factors of the transforming growth factor-β (TGF-β) superfamily, TGFβs, activins, growth differentiation factors (GDF), bone morphogenic proteins (BMPs),
play an essential role in embryonic development, tissue morphogenesis, cell proliferation
and cell differentiation [37]. Several members of the TGF-β superfamily have been
correlated to the biological processes of bone induction, including mesenchymal cell
recruitment, proliferation, and extracellular matrix (ECM) production [38]. BMPs,
particularly BMP-2, BMP-4, and BMP-7, are the most extensively utilized osteogenic
factors for inducing de novo bone formation in ectopic and orthotopic sites, including
critical size defects (CSD) [39]. Among BMPs, recombinant human BMP2 is currently
FDA approved and available in a recombinant form for use as a potent osteogenic factor in
specific medical applications such as spine fusion and alveolar ridge augmentation [40].
On the other hand, angiogenic growth factors that induce vascularization are
essential for the formation and homeostasis of bone because of their role in the transport
of oxygen, nutrients, growth and differentiation factors, and circulating cells [41]. The
presence of a microvascular network supports the osteogenic, chondrogenic, and
mesenchymal stem cells required for bone repair. Angiogenesis is regulated by growth
factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor
(PDGF), fibroblast growth factor (FGF) and insulin-like growth factor (IGF) [42]. Recent
studies have shown that the delivery of VEGF was found to increase blood vessel density
and stimulate bone regeneration in rabbit and rat critical-size bone defects [43].

5

Additionally, it has been shown that the combined delivery of VEGF with osteoinductive
growth factors synergistically enhances osteogenesis [44]. Dual delivery of osteogenic and
angiogenic factors is a novel strategy in bone regeneration engineering [45]. VEGF and
BMP2 have been widely used in the fields of tissue engineering and regenerative medicine
to stimulate angiogenesis and bone formation [46]. These two growth factors have additive
effects and synergistically enhance bone regeneration [46]. VEGF and BMP-2 stimulated
the chemotaxis of BMSCs. In vivo, these two growth factors also have been confirmed to
induce the homing of tail vein injected BMSCs to the site of scaffold subcutaneous
implantation in nude mice.
However, concerns about these bioactive strategies remain, such as the
uncontrollable release and types of the delivered growth factors, and a high degradation
rate resulting from a high in vivo instability of the angiogenic factors [47]. For the clinical
therapy, BMP-2 in a high dosage needs to be used which associated with a high cost as
well as a side effect, such as excessive bone resorption and promotion of tumor
angiogenesis [4]. Additionally, it has been reported that the extent of bone formation in
vivo depends on the exposure duration of osteoprogenitor cells and endothelial progenitor
cells to BMP2 and VEGF [4, 47].
1.3.1 Carriers for Controlled Growth Factor Delivery. Direct administration of growth
factors is not recommended in vivo. Injecting high doses of potent growth factors into the
body may lead to severe side effects because of the extremely high initial concentration,
and short half-lives due to the rapid degradation and cleaving. Since growth factors
undergo rapid degradation, encapsulation within a material carrier can provide protection
from enzymes and enhanced growth factor retention at the target site [35]. Additionally,
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controlled release prevents unwanted cytotoxic and inflammatory effects as well as ectopic
bone formation. A variety of natural, synthetic and inorganic materials have been used as
controlled delivery systems [48]. Synthetic polymers including poly(α-hydroxy acids),
poly(orthoesters), poly(anhydrides), poly(amino acids) and copolymers of lactic and
glycolic acid have been investigated for encapsulated delivery for their controllable
physicochemical properties [35]. For instance, PLG-based nano- or microcapsules
encapsulating growth factors formed by a double emulsion–solvent evaporation method
are widely used. Sustained delivery of encapsulated VEGF in PLG microspheres may
upregulate angiogenesis [34]. The degree and mechanism of growth factor encapsulation
are dependent on hydrophobic–hydrophobic or hydrophilic–hydrophilic interactions
between the molecules and polymers [34]. Several studies have revealed that the release
profile of recombinant human BMP-2 from PLGA microparticles is controlled by the
molecular weight, lactic to glycolic ratio, end-group functionalization, and amount of
incorporated growth factor [35, 49, 50].
Several studies have shown that PLGA microparticles sustain retention and release
of rhBMP-2 and rhBMP-7 to adequately bridge rat and ovine critical-size cranial defects,
respectively [49, 50]. However, the release profiles were affected higher by the
functionalization of acidic moieties to PLGA end groups, which increased the degradation
of the vehicle, resulting in the early release of encapsulated growth factor and sub-optimal
bone formation [49, 50].
Natural materials including silk, keratin, collagen, gelatin, fibrinogen, elastin,
chitosan, hyaluronic acid, cellulose, and alginate have also investigated as growth factor
carriers [34]. For example, gelatin microspheres and gelatin combined with glycidyl
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methacrylated dextran have been used to deliver certain growth factors such as BMP-2 and
IGF-1 [27, 34]. For immobilization and timed-release of BMP2 and VEGF, PLGA microand nanoparticles are used due to their wide range of degradation times. However, protein
denaturation because of surface adsorption and acidic degradation products of PLGA can
significantly reduce protein bioactivity [4]. Another example of classical sustain release of
GFs is the colloidal micro/nanoparticles where the GFs formulated in poly(lactic
acid)/poly(D,L-lactic-co-glycolic acid) (PLA/ PLGA) particles for delivery. Drawbacks of
these particles include low encapsulation efficiency and burst initial release, as well as the
complex formulations to retain GF stability [51]. These biopolymers can be formulated
into a variety of physical structures relevant to growth factor-delivery using several
methods but common major issues are the maintenance of the bioactivity of the
encapsulated growth factors and degradation rate [34, 52]. The development of new
vehicles for bone regeneration focuses on promoting local growth factor retention and
sustained release for augmenting osteoinductivity in vivo [48]. The release profiles of a GF
of particulate carrier systems are eventually determined by the rate of vehicle degradation,
loaded amount of growth factor, growth factor diffusion, and particulate size [35].
Therefore, there is a need for delivery strategies that respond to local signals or externally
applied signals to control the release, so-called ‘the on-demand release’ [34, 53]. The ondemand release by external triggering signal can be engineered by the incorporation of
stimuli-responsive components within the delivery systems. The most commonly used
triggering mechanisms involve proteins such as enzymes that cleave a cross-linker used to
immobilize a growth factor [34, 53].
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The engineering of multi-functional nanomaterials that enable the simultaneous,
spatially-controlled, and sequential release strategies of dual growth factors are necessary
to recapitulate the early expression factors for bone regeneration.
1.4 Scaffolds in BTE
One key feature of TE is to develop biomimetic scaffolding materials that can
harmonize the proliferation, self-renewal, and differentiation of multipotent stem cells into
different lineages [54]. The interactions between cells and materials guide many cellular
activities. These interactions of cell-material can direct the cell shape and the cytoskeletal
organization that in turn regulate the biological processes, such as cell adhesion, growth,
differentiation, and apoptosis [55]. Mammalian cells can sense and interact with the
extracellular microenvironment at the nanometer scale despite their micrometer
dimensions [54]. Bone tissue engineers have suggested that scaffolds have to be mimic the
structure and properties of natural bone ECM [56]. Thus, the ideal scaffold for BTE should
satisfy basic scaffold requirements such as porosity to allow vascularization,
biocompatibility, and biodegradability with a controllable rate to accommodate the growth
and maturation of cells, and appropriate surface characteristics for cell proliferation,
migration, and differentiation [57-59].
Typically, these specific properties for an ideal scaffold are found in hydrogels.
Hydrogels are three-dimensional polymeric networks that can retain a large volume of
water and swell in a physiological environment without dissolving [60]. The hydrogel
affords efficient cell delivery into the bone defect site, cell niche establishment, and
enhancement of mineralization [4]. Their unique properties, including similarities with the
ECM, hydrophilicity, high permeability to oxygen and nutrients, and inherent cellular
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interaction capabilities, make them leading candidates for engineered tissue scaffolds [1,
61], Figure 2.
1.4.1 Physical Versus Chemical Crosslinking Hydrogels. The hydrogel 3D network can
be formed via physical or chemical crosslinking methods. An increased interest in
physically cross-linked hydrogels is due to the absence of cross-linkers reagents used for
formation. The formation of physical bonds achieves the physical crosslinking through
hydrogen bonds or van der Waals interactions between the constitutive polymer chains.
For instance, Polyacrylic acid (PAA) and polymethacrylic acid (PMAA) make complexes
with polyethylene glycol (PEG). These complexes have hydrogen bonding between the
oxygen of the PEG and the carboxylic group of PAA/PMAA[62]. These physical
crosslinks may not be irreversible in nature, but they are adequate to form hydrogels
insoluble in aqueous biological solutions. So, these physical crosslinking can absorb the
water but network defects may happen due to free chain ends or chain loops [29].
On the other hand, an increased interest in chemically cross-linked hydrogels is due
to the excellent mechanical strength of chemically cross-linked hydrogels [62]. The
chemical crosslinking is achieved by the formation of stable covalent bonds, mediated by
crosslinking agents, between the polymer chains [63, 64]. Hydrophilic polymers have
certain functional groups such as NH2, COOH, OH that may be used for the formation of
hydrogels. The reactions such as an amine-carboxylic acid or an isocyanateOH/NH2 reaction or Schiff base formation may be used to form covalent linkages between
polymer chains [62, 64]. The chemically cross-linked method is highly versatile to improve
the mechanical property of the hydrogels. Although, cross-linking agents are often toxic
compounds. The harmful effects of chemical cross-linking can be avoided by the process
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of using radiation or electron beam method. Radiation cross-linking is more advantageous
as the degree of cross-linking can be managed by the amount of dose used and is an energyefficient and cleaner process with no harmful residuals in the products [62, 64].
1.4.2 Natural Versus Synthetic Hydrogels. Hydrogels are categorized according to their
source (natural or synthetic). Hydrogels can be made of wide range of natural
biodegradable polymers such alginate, chitosan, hyaluronic acids, collagen, gelatin, and
keratin or synthetic polymers such as polyethylene glycol (PEG), polyvinyl alcohol (PVA),
poly(ε-caprolactone) (PCL), poly glutamic acid (PGA), and poly methacrylic acid [61].
Natural hydrogels are recognized as a nature-inspired biomaterial with similarity
with the extracellular matrix (ECM), attractive biocompatibility and biodegradability traits.
Because of their similarity to ECM, the natural hydrogels may avoid the stimulus of
inflammation or immunological response and toxicity [52]. Also, these biomaterials may
potentially incorporate peptide sequences within their backbone, such as arginine–glycine–
aspartate (RGD) or matrix metalloproteinases (MMPs) sensitive domains that allow
modulating the cells attachment, as well as their migration and proliferation within the
hydrogel along with its controlled degradation [52, 64, 65]. Natural hydrogels provide a
conductive matrix for cell adhesion and migration. However, they lack sufficient
mechanical strength to prevent soft tissue compression [64]. On the other hand, synthetic
hydrogels provide tremendous flexibility in the design of polymers with defined physical
and mechanical properties. Nevertheless, they lack bioactive recognition ligands to support
cell-matrix interactions required for adhesion, proliferation, differentiation, and maturation
of the seeded cells. This limitation had been overcome by conjugating bioactive ligands or
peptide sequences of the extracellular matrix (ECM) proteins to the synthetic matrix. For
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instance, the focal adhesion RGD sequence that interacts with integrin binding receptors
on the cell surface is the most widely used peptide. Hydrogels have been used as BTEmatrices capable of mimicking ECM topography and delivering bioactive proteins [1]. For
example, osteogenic differentiation of MSCs requires a supporting matrix with high
modulus and slow degradation, whereas vasculogenic differentiation of progenitor ECs
requires a low modulus and relatively fast-degradation of the matrix. For matrices with
high modulus and slow degradation rate, many research groups have demonstrated that
hydrolytically degradable PEG-based hydrogels, such as linear polyethylene glycol-colactide acrylate (LPELA), are potentially useful as a delivery matrix for stem cells in
regenerative medicine, (Table 1). They have also implicated gelatin methacrylate (GelMA)
as a delivery matrix with low modulus and fast-degradation which afford cell-responsive
properties [66].
1.5 Cells Sources for BTE
Selecting the appropriate cell type as part of a TE approach to produce a functional
bone graft substitute is vital for the success of the implant. The choice of cells is determined
by several criteria in order to achieve effective, successful repair of defected tissues [67].
A sufficient number of cells have to be introduced to fill the defect, cells have the capacity
to differentiate into desired phenotypes, cells have to adopt appropriate 3D structural
scaffold and produce tissue-like ECM as well as signaling molecules, cells must be
structurally and mechanically adaptable with the host cells, cells have to successfully be
able to integrate with the host cells and overcome the risk of immunological rejection [59,
67, 68]. The source of the selected cells can be from the patient (autologous), from a human
donor but not immunologically identical (allogenic), or from a different species donor
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(xenogenic) [69]. Autologous cells consider an excellent source for use in TE due to the
low association with immune complications. However, these cells are not cost-effective
and batch controlled for universal clinical use [70]. Conversely, allogenic cells provide
advantages in terms of uniformity, standardization of procedure, quality control and costeffectiveness [70]. Furthermore, the source of cells can be categorized into non-stem cells
(mature), or stem cells (adult and embryonic stem cells), and zygotes (totipotent stem
cells). The use of mature cells is constrained due to its low potential in proliferation and
differentiating [70].
Stem cells are undifferentiated cells that can self-renew and commit to specific cell
lineages in response to stimuli that provide excellent regenerative potential which will most
likely lead to the functionality of the engineered tissue [71]. Because of their capacity for
expansion and potential to differentiate into BTE, pluripotent stem cells, and multipotent
stem cells have become the cell types of choice. Pluripotent stem cells encompass
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) whereas
multipotent stem cells include mesenchymal stem cells (MSCs) and other tissue-specific
adult stem cells along with hematopoietic stem cells (HSCs) [72]. Embryonic stem cells
(ESCs), umbilical cord blood mesenchymal stem cells (CB-MSCs), induced pluripotent
stem cells (iPSCs), and adult stem cells, are among the major candidates for BTE
applications [73, 74]. Additionally, an adipose-derived stromal vascular fraction (SVF) is
a useful and inexhaustible source for vascularization applications, where regenerating
vascularized bone tissues is required [73, 74].
ESCs are isolated from the inner cell mass of the blastocyst during embryological
development. ESCs have a high multilineage differentiation capacity and able to self-renew
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over long periods, which make them promise for use in regenerative medicine. However,
there are ethical considerations, regulatory constraints, and teratomas production when
transplanted in vivo associated with ESCs [75]. Due to limited and controversial
regulations associated with ESCs, cord blood has been found to be an excellent source of
fetal MSCs and is safer than ESCs for clinical applications [76].
Umbilical cord blood mesenchymal stem cells (CB-MSCs) are known by their high
availability due to the existence of cord blood banks, broad differentiation and proliferation
potential, and higher in vivo safety since CB-MSCs have not been reported as teratomas
producer when implanted in vivo [73, 77]. The umbilical cord contains 60–80 cm3 of cord
blood that contains ESCs and MSCs, as well as hematopoietic stem cells and endothelial
progenitor cells (EPCs). However, more studies are needed to confirm the potential of CBMSCs for TE applications [73, 77].
Induced pluripotent stem cells (iPSCs) are other attractive stem cell sources for TE due
to their ability to be reprogramed, enabling the generation of multiple cell types from a
single cell [78]. Human iPSCs have been demonstrated for tissue repair and regeneration,
enabling researchers to overcome the ethical and immunological limitations associated
with the use of ESCs. Furthermore, iPSCs can be derived from a patient's own cells; as a
result, they can be used to model diseases and for screening drugs in human in vitro [79].
Taking these into account, implantation of iPSCs in critical-sized defect of immunedeficient mice has been reported to promote new bone formation and partial repair of the
defect [43]. In Japan, depending on recent clinical trials involving patients who had
debilitating eye diseases, iPSCs are being represented as promising cell sources in clinical
settings [44].
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Adult stem cells are located in many types of adult tissue including bone marrow,
peripheral blood, adipose tissues, nervous tissues, and muscles [80]. For example,
mesenchymal stem cells (MSCs) which reside in the bone marrow can differentiate into
osteoblasts (bone), chondrocytes cells (cartilage), myoblasts (muscle), and adipocytes (fat),
while neural stem cells (NSCs) either differentiate to astrocytes in order to support cells in
the nervous system of vertebrates or oligodendrocytes (neurons), respectively [81]. In vivo,
self-renewal and differentiation of stem cells are determined by signals from their
surrounding microenvironment or “niche” [82]. This niche is composed of several other
cell types as well as numerous chemicals, mechanical and topographical cues at the microand nano-scales, which are believed to serve as signaling mechanisms to determine cellspecific recruitment, migration, proliferation, differentiation as well as the production of
numerous proteins required for hierarchical tissue organization [83].
Among cells with therapeutic potential, mesenchymal stem cells (MSCs) have had
more attention because they are capable of self-renewal and can differentiate into several
types of mesenchymal tissues, including cartilage, bone, and adipose tissue
[84]. Additionally, MSCs are very promising for TE applications because of their high ex
vivo proliferation capacity and the low donor-site morbidity of the harvesting procedure
[85, 86]. It has been demonstrated in various animal models that ex vivo-expanded MSCs
are capable of stimulating the regeneration of skeletal defects after implantation [87, 88].
1.6 Cells Sources for Vascularization
Since bone is particularly a highly vascularized tissue, the synergistic development
of vasculature and mineralized matrix needs a synchronal interaction between osteogenic
and endothelial progenitors [89]. In TE, successful engineered grafts will need a
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microvascular network to supply oxygen and nutrients to the cells as well as removing
wastes [90]. One of TE approaches for creating a microvascular network is through
stimulating pre-vasculogenesis in situ by seeding vascular progenitor cells into a
biodegradable scaffold engineered with the appropriate mechanical properties and then
promoting cell growth and differentiation in vitro [91]. Capillaries and vessels are
generated de novo (vasculogenesis) in vitro culture systems by endothelial or endothelial
progenitor cells (EPC) instead of existing vasculature (angiogenesis) [92], figure 3. The
generation of vasculature within a TE tissue will depend on several factors: progenitor EC
type, the microarchitecture of the scaffold material, the biochemical environment, and
mechanical signals [89]. Vascularization supported by cell-based therapies has gained
more attention using differentiated macrovascular endothelial cells (ECs) or endothelial
progenitor cells (EPCs) [92, 93]. Mature ECs have been well-established to stimulate
angiogenesis. Among them, human umbilical vein endothelial cells (HUVECs),
microvascular endothelial cells (MVECs) and human aortic endothelial cells (HAECs) are
well-known applied primary endothelial sources for TE vascular graft (TEVG)
construction [92]. HUVECs, MVECs, and HAECs are derived from vessel walls,
considered to be differentiated, mature endothelial cells (ECs), and are employed as
“controls” for EPC studies [94]. Although human MVECs have been reported to reseed
decellularized vasculature in vitro successfully, the graft stimulates hematoma formation
after transplantation and occlusions within capillaries after implantation for one week [95].
While HUVECs, which represent one of the most commonly employed cells in
vascularized BTE. These cells naturally generate vessel-like structures when cultured in
hydrogels [15, 89, 96].
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Contrarily with mature ECs, EPCs have been found to be ten times more
proliferative than HUVECs and have a higher capacity to contribute to angiogenesis [97].
EPCs are heterogeneous ECs in different stages of differentiation, from hematopoietic bone
marrow progenitors to mature endothelial cells that have a role in adult vascular repair [98].
EPCs are mostly unipotent stem/progenitor cells with the implicit in differentiating into
mature ECs. Accumulated data suggest the significance of EPCs for neovascularization,
vascular remodeling, curing vascular diseases, enhancing the reconstruction of ischemic
regions, and promoting angiogenesis in regenerative medicine [99-102].
EPCs types have been described based on isolations from various sources as well
as for sharing similar phenotypic characteristics into Haematopoietic EPCs, Nonhaematopoietic EPCs, and Tissue-resident EPCs [103]. EPCs that are isolating and
culturing endothelial cells from the peripheral blood have gained most of the attention and
been categorized into two different types according to their morphologies, appearance time,
and protein expression [97, 103]. According to their surface morphology, EPCs showed
different types of cells, spindle-shaped and cobblestone-shaped cells. The “spindleshaped” ECs were later termed early EPCs (eEPCs) while ECs with a “cobblestone”
morphology are referred to as late EPCs (lEPCs), or endothelial colony-forming cells
(ECFCs)[97, 103].
ECFCs have attracted significant attention because ECFCs are the only population
that has all the characteristics of a real EPCs [94]. ECFCs are a subset of progenitor cells
that circulate in peripheral blood and contribute to the formation of new vasculature [104,
105]. ECFCs exhibit clonal proliferative ability, present endothelial cell surface markers,
and possess prominent postnatal vascularization potential in vitro and in vivo [105]. The
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identification of ECFCs in humans opened a promising avenue to noninvasively isolate
large quantities of autologous ECs for clinical application [104, 106]. Several preclinical
studies have demonstrated the inherent and robust vasculogenic properties of ECFCs and
their therapeutic potential to endothelialize cardiovascular grafts in vivo [105-107].
Furthermore, ECFCs can self-assemble into long-lasting microvascular networks that
integrate with the host vasculature after post-transplantation into immunodeficient mice
[108].
In several studies, ECFCs have been used for the generation of prevascularized TE
constructs in combination with other cells and biocompatible scaffolds [109]. Natural or
synthetic scaffold mimic structural and functional properties of the natural ECM and can
be regulated by physicochemical processes to optimize the biomechanical properties of the
scaffold to maintain the cell function, the progression of the vascular network, and tissue
regeneration [108, 109]. This approach provides better control of the microenvironmental
components that govern blood vessel assembly [110]. It also provides the potential to
coculture other cell types that either promote angiogenesis or give rise toward tissuespecific cell lineage [109]. Additionally, it allows regulating the biological activity of
ECFCs by changes in the structure of biocompatible scaffold or by introducing of trophic
mediators that assist neovascularization and regeneration [110]. Previous studies with
ECFCs encapsulated in Matrigel reported that these cells generated functionally longlasting and host-interconnected vascular networks in vivo particularly in coculturing with
MSCs or ADSCs [33, 110-112]. ECFCs can also employ as paracrine mediators before the
initiation of blood perfusion, regulating the regenerative potential of MSCs [104]. It has
shown that MSCs are highly dependable on PDGF-BB and that ECFCs provide essential
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angiocrine factors required to preserve MSCs as viable [4, 104]. This early angiocrine
ultimately supports extensive engraftment and long-term differentiation of transplanted
MSCs [104].
1.7 Challenges to BTE Approaches
Despite the wealth progress that has been made in the field of TE, critical obstacles
must be overcome in order to generate functional tissues. The first challenge is the demand
to use massive doses of growth factors to differentiate cells to compensate their
degradation, poor retention time as well as control of the sustained delivery of growth
factors to the progenitor cells [4, 113, 114] effectively. The second challenge is the lack of
sufficient scaffold vascularization.
Regarding growth factors, since they undergo rapid degradation, encapsulation
within a material carrier can provide protection from enzymes, enhanced growth factor
retention at the target site, and sustained growth factor release [35]. Furthermore, it has
been reported that the extent of bone formation in vivo depends on the exposure time of
osteoprogenitor cells and endothelial progenitor cells to BMP2 and VEGF, respectively.
Therefore, the controlled delivery system of growth factors becomes increasingly
necessary and vital [4].
Hence, to address the first challenge a set of self-assembled, plasmin-cleavable NPs
for on-demand release of BMP2 in response to enzymes secreted by hMSCs and ECFCs
encapsulated in a micropatterned composite hydrogel for induction of vascularized
osteogenesis. To do this, polyethylene glycol (PEG) chain-extended with self-assembling
peptide glycine-(phenylalanine)3 (GFFF) and the plasmin-cleavable GGKFKTGG peptide
were used to form self-assembled NPs and facilitate a wide range of timed release for
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rhBMP2. Regarding VEGF delivery, nanogel (NG) was engineered to control the release
rate of VEGF in the patterned hydrogel. To do this, polyethylene glycol (PEG) chainextended with short lactide (L) and glycolide (G) segments were used to form selfassembled NGs and facilitate a wide range of timed release of VEGF.
Regarding lack of sufficient vascularization, TE encounters a mass transfer
challenge that limits scaffold construct size in vivo regardless of tissue-specific goals. The
majority of progenitor cells are encapsulated within 100-200 microns of capillaries where
sufficient oxygen and nutrition is provided, and metabolic waste can be transported [113,
115]. Therefore, successful regeneration of large bone defects needs early induction of
vascularization in the scaffold [4, 115].
As it is mentioned earlier, one of TE approaches for creating a microvascular
network is through stimulating pre-vasculogenesis in situ by seeding vascular progenitor
cells into a biodegradable scaffold engineered with the appropriate mechanical and
patterning properties and differentiating them using vascular endothelial growth factor
(VEGF). The second approach is to induce prevascularization in vitro by using a co-culture
system of vascular progenitors’ cells and osteoprogenitor cells. Cells that are cultured in
conjunction with ECs may have either a direct or indirect effect on the development of
vascular networks in tissue-engineered constructs [92]. Mesenchymal stem cells (MSC)
have been reported to provide structural support for neovessel formation. The co-culture
of MSCs with endothelial progenitor cells such as EPC and HUVEC cells has been reported
to induce MSC to differentiate into mural [92, 116]. It is remarkable that the ultimate
effective bone regeneration and vessel formation in a critical-sized defect is also related to
the close association and interaction between angiogenesis and osteogenesis.
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Hence, to address the second challenge, micropattern channels loaded with a
suspension of hMSCs + ECFCs and NG-VEGF in a crosslinked gelatin methacryloyl
(GelMA) hydrogel. While hMSCs and NP-BMP2 were encapsulated in a patterned matrix
based on acrylate-functionalized lactide-chain-extended linear polyethylene glycol
(LPELA) hydrogel. This system will be designed to form an osteoblastic-vascular niche in
the structure of the engineered scaffold.
It should be also emphasized that osteogenesis and vascularization processes are
coupled during the bone formation and regeneration as the maximum extent of
osteogenesis follows the maximum level of vascularization and vice-versa. Therefore, in
this work, a patterned hydrogel was designed to facilitate controlling both osteogenesis and
vasculogenesis processes in the scaffold and consequently increase the extent of bone
formation.
Accordingly, the following aims are considered for testing the hypothesis toward
the objectives.
Aim 1. To evaluate the temporal expression of proteases by the encapsulated
hMSCs and ECFCs.
Aim 2. To synthesize biodegradable, self-assembled, polyethylene glycol-based
nanoparticles and evaluate with respect to size, degradation rate and the release kinetics of
BMP2- grafted nanogels.
Ami 3. To evaluate the extent of vasculogenesis and osteogenesis of human
mesenchymal stem cells (hMSCs) and human colony-forming endothelial cells (ECFCs)
encapsulated in a patterned hydrogel with the spatiotemporal release of BMP2 and VEGF.
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Figure 1.1 TE approach for reconstruction of large bone defects

Figure 1.2: Applications of hydrogels in TE
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Figure 1.3: Synchronize vasculogenesis and osteogenesis in BTE
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CHAPTER 2: PLASMIN-CLEAVABLE NANOPARTICLES FOR ONDEMAND RELEASE OF MORPHOGENS IN VASCULARIZED
OSTEOGENESIS1
2.1 Introduction
A major obstacle to the use of tissue engineered (TE) constructs for the reconstruction
of skeletal defects is insufficient vascularization and slow rate of bone regeneration [117].
Bone morphogenetic proteins (BMPs) are used as potent osteogenic factors in certain
clinical applications like spinal fusion to accelerate bone formation [118]. In addition to
BMPs, rate of bone formation can be regulated by angiogenic factors like vascular
endothelial growth factor (VEGF) via the crosstalk between the differentiating
mesenchymal stem cells (MSCs) and endothelial colony-forming cells (ECFCs) [119].
VEGF is predominantly expressed during the early phase of bone formation to vascularize
the regenerating volume whereas BMPs are continuously expressed during mineralization,
callus formation and remodeling [120]. Several studies by us and others have shown that
sustained delivery of bone morphogenetic protein-2 (BMP2) enhances osteogenic
differentiation of MSCs [121-123]. In a previous study, we demonstrated that sustained
release of VEGF from nanogels (NGs) in the first five days within the microchannels of a
patterned construct and sustained release of BMP2 from NGs over three weeks within the
matrix of the construct considerably increased the extent of vasculogenesis and

1

Safaa Kader, Mehri Monavarian, Danial Barati, Seyedsina Moeinzadeh, Thomas M.
Makris, Esmaiel Jabbari. Biomacromolecules 2019, 20, 8, 2973-2988. Reprinted here with
permission of publisher.
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osteogenesis by the encapsulated MSCs and ECFCs [4, 124]. Further, the timed-release of
EGF and BMP2 from the NGs significantly increased the expression of basic fibroblast
growth factor (bFGF) which was attributed to the coupling of paracrine signaling between
the MSCs and ECFCs [4]. Cell-mediated delivery systems are reported to improve
temporal bioavailability of growth factors [125, 126]. We hypothesized that on-demand
release of osteogenic and vasculogenic morphogens in response to enzymes secreted by
human MSCs (hMSCs) and ECFCs could further enhance the exchange of paracrine factors
between the two cell types, leading to robust bone formation. Further, the on-demand
release could potentially mitigate the adverse effects of BMP2 in spinal fusion and other
clinical orthopedic applications [127].
An exciting approach to the on-demand release of morphogens in tissue regeneration
is the use of enzymatically-responsive systems that release the morphogen in response to
proteases secreted by stem cells and their progenies [128, 129]. In particular, MSCs and
ECFCs express proteases to degrade the extracellular matrix (ECM) as they migrate to the
site of injury [130, 131]. MSCs invade the ECM during angiogenesis via different protease
families including the plasmin axis of serine proteases and the plasmin-independent matrix
metalloproteinases (MMPs) [132]. Human MSCs have a strong fibrinolytic activity by
expressing key elements of the fibrinolytic cascade including urokinase plasminogen
activator (uPA) and its receptor (uPAR), tissue plasminogen activator (tPA) and
plasminogen inhibitor PAI [133]. Further, it has been shown that the expression level of
fibrinolytic enzymes tPA and uPA in hMSCs is dependent on factors that mediate
vascularization and bone formation like basic fibroblast growth factor (bFGF),
transforming growth factor-β (TGF-β) and interleukin-1β (IL-1β) [134]. Studies on
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fibrinolytic capacity of MSCs in a fibrin clot indicate that the activity of plasmin and the
extent of fibrin degradation during wound healing is controlled by MSCs [134-136].
Therefore in this work, the plasmin-specific lysine-phenylalanine-threonine-lysine
(KFTK) peptide was used for enzymatic degradation of PEG-based nanoparticles (NPs) in
response to plasmin-related proteases secreted by hMSCs and ECFCs [137].
Peptides due to their sequence diversity, specificity, and tunable configuration have
been used extensively as building blocks for self-assembled nanostructures in drug delivery
and tissue engineering [138-140]. Among these the oligopeptides diphenylalanine (FF),
triphenylalanine (FFF), tetraphenylalanine (FFFF) and their derivatives assemble into a
variety of micro- and nano-structures by aromatic interaction between the phenyl side
chains [138, 141-143]. For example, the oligopeptide FF assembles into highly ordered
nanotubes and nanowires in response to changes in temperature or ionic strength [138, 144]
and the structure can be changed from tubular to fibrillar or spherical by FF modification
with Fmoc-protecting or thiol groups [144]. Similarly, oligopeptide FFF and its derivatives
assemble into a wide range of nanostructures from spheres to plates, rods, doughnuts, and
needles [130, 143]. Conjugation of polyethylene glycol (PEG) to these peptides enhances
water solubility and biological stability and reduces immunogenicity of the peptides [145].
In this regard, conjugation of oligopeptide FFKLVFF to PEG produced a fibrillar
nanostructure with FFKLVFF and PEG as the core and corona, respectively [145]. In
another study, PEG-FFFF conjugates self-assembled into nanotubes, fibers, and wormlike
micelles as the length of the PEG macromer was increased [146]. Due to the structural
diversity of phenylalanine oligopeptides, we used the short peptide FFF in this work to
generate self-assembling and enzymatically-cleavable PEG-peptide NPs.
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The objective of this work was to synthesize self-assembled, plasmin-cleavable NPs
for on-demand release of BMP2 in response to enzymes secreted by hMSCs and ECFCs
encapsulated in a micropatterned composite hydrogel for induction of vascularized
osteogenesis. The following approach was used to achieve the objective. The sequence
triphenylalanine (FFF) was used for self-assembly; [130, 140, 143] the sequence lysinephenylalanine-threonine-lysine (KFTK) was used as a plasmin-cleavable peptide ;[132,
147] and short glycine (G) sequences were used as spacers in synthesizing the PEG-peptide
conjugate.

The

difunctional

cysteine-terminated

(C)

peptide

CGGK(GFFF-

acetyl)GGKFKTGG was synthesized in the solid phase using doubly-protected α-Fmoc
and ε-MTT lysine (Figure 2.1a). The peptide was conjugated to polyethylene glycol
diacrylate (PEGDA) by the reaction between cysteine and acrylate groups (Figure 2.1b).
Next, the chain-ends of the PEG-peptide conjugate were functionalized with succinimide
(suc) groups (Figure 2.1c) and the suc-peptide-PEG-peptide-suc macromer was selfassembled in aqueous solution to form NPs, hereafter referred to as PxSPCP NPs (Figure
2.1d). Then, BMP2 was grafted to the NPs by the reaction between succinimide and amine
groups to form BMP2-PxSPCP NPs (Figure 2.1e). The vasculogenic protein VEGF was
conjugated to the self-assembled hydrolytically-degradable NGs based on PEG with short
lactide and glycolide segments as previously described [4]. The BMP2-PxSPCP NPs were
characterized with respect to size, particle stability, grafting efficiency, protein stability
and release, and osteogenic differentiation of hMSCs. The synthesized BMP2-PxSPCP
NPs were tested in a patterned, cellular, composite hydrogel encapsulating hMSCs and
ECFCs with respect to osteogenesis and vasculogenesis. A hydrogel construct patterned
with microchannels was generated using a cylindrical mold inserted with needles through
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two end-caps as we previously described (Figure 2.2a) [4]. The needle-inserted mold was
filled with a suspension of hMSCs and BMP2-PxSPCP NPs in acrylate-functionalized
poly(ethylene glycol-co-lactide) (LPELA) hydrogel (Figure 2.2b) and crosslinked. After
removing the needles, a suspension of ECFCs+hMSCs and VEGF-NGs in gelatin
methacryloyl (GelMA) was injected in the microchannels and crosslinked (Figure 2.2c).
The constructs with spatiotemporal patterns of cells and growth factors were cultured in
vasculogenic/osteogenic medium (without VEGF or BMP2) and characterized with respect
to cellularity, expression of osteogenic and vasculogenic markers, mineralization, and
vasculogenesis.
2.2 Materials and Methods
Lactide (L) monomer with >99.5% purity (Ortec, Easley, SC) was dried as
described.[4] PEG with molecular weights (MW) of 2.0, 5.0 and 7.5 kDa, PEGDA with
575 Da MW, porcine skin gelatin (type A, 300 bloom), tin (II) 2- ethylhexanoate (TOC),
dimethyl sulfoxide (DMSO), methacrylic anhydride (MA), Alizarin red, and 4,6
diamidino-2-phenylindole (DAPI) were received from Sigma-Aldrich (St. Louis, MO).
Dichloromethane (DCM, Acros Organics, Pittsburg, PA) was dried by distillation over
calcium hydride. Diethyl ether, dimethylformamide (DMF) and hexane were received from
VWR (Bristol, CT) and used as received. Dialysis tubing with 0.1-0.5 kDa and 3.5 kDa
cutoff MW was received from Spectrum Laboratories (Rancho Dominquez, CA). N,N′disuccinimidyl carbonate (DSC) and bovine serum albumin (BSA) were received from
Novabiochem (San Diego, CA) and Jackson ImmunoResearch (West Grove, PA),
respectively. EBM2 medium, EGM-2 BulletKit medium, human basic fibroblast growth
factor (bFGF), R3-insulin-like growth factor-1 (IGF-1), human epidermal growth factor
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(EGF), ascorbic acid (AA), β-sodium glycerophosphate (βGP), dexamethasone (DEX),
hydrocortisone, gentamycin sulfate (GS), penicillin (PN), streptomycin (SP), and
amphotericin-B were received from Lonza (Hopkinton, MA). PECAM-1 (CD31) and
bovine anti-rabbit IgG-FITC (secondary antibody) were received from Santa Cruz
Biotechnology (Dallas, TX). Human VEGF, rhBMP-2 (hereafter referred to as BMP2),
their Enzyme-Linked Immunosorbent Assay (ELISA) kits, and bFGF (FGF2) ELISA kit
were received from MyBioSource (San Diego, CA). Human plasminogen and MMP-2
ELISA kits were received form Innovative Research (Court Novi, MI) and Boster
(Pleasanton, CA), respectively. Acetomethoxy derivative of calcein (cAM) and ethidium
homodimer (EthD) were received from Life Technologies (Grand Island, NY), and MTS
cell viability assay was received from ThermoFisher (Waltham, MA). Quant-it PicoGreen
dsDNA reagent kit was received from Invitrogen (Carlsbad, CA). The kits for
QuantiChrom calcium and alkaline phosphatase (ALP) assays were received from
Bioassay Systems (Hayward, CA).
2.2.1 Material Synthesis. A two-step procedure was used to synthesize linear LPELA
macromonomer as we previously described [66, 148, 149]. Acrylamide-terminated
glycine-arginine-glycine-aspartic acid (Ac-GRGD) cell-adhesive peptide was synthesized
and purified as we previously described [150]. GelMA was synthesized by the reaction of
gelatin with methacrylic anhydride as we previously described [124, 151]. PEG with PEG
MW of 12 kDa was chain-extended with short lactide (L) and glycolide (G) blocks
(LG/PEG molar ratio of 24 and L:G ratio of 60:40), the chain-ends were terminated with
succinimide groups, the macromers were assembled into NGs by dialysis, and VEGF was
grafted to the NGs to generate VEGF-NGs as we previously described [4]. The grafting
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efficiency of VEGF to the NGs was 92±1%. VEGF was released steadily from VEGF-NGs
in 7 days, as we previously measured by ELISA [4].
2.2.2 Synthesis of Plasmin-Cleavable NPs. The following approach was used to
synthesize the PEG-SPCP conjugate as illustrated in Figure 2.1. The sequence cysteineglycine-glycine-lysine with doubly-protected lysine residue [CGGK(α-Fmoc)(ϵ-MTT)]
was synthesized in the solid phase on Wang resin as described [126, 152]. The acetylterminated triphenylalanine with a glycine spacer (GFFF-ac) was synthesized separately in
the solid phase on Wang resin and coupled to the MTT terminus of CGGK to yield the
CGGK(GFFF-ac)(α-Fmoc) sequence. After MTT deprotection, the sequence plasmincleavable KFKT with two glycine spacers on each side (GGKFKTGG) was coupled by
EDC chemistry to the Fmoc terminus of CGGK(GFFF-ac)(α-Fmoc) to yield the
CGGK(GFFF-ac)GGKFKTGG peptide (SPCP) (Figure 2.1a). After cleaving from the
resin, the SPCP peptide was purified by high-performance liquid chromatography (HPLC)
and characterized by electrospray ionization spectrometry as we previously described
[150]. The peptide CGGK(GFFF-ac)GGG without the KFKT sequence (SP) was
synthesized to produce NPs that did not undergo cleavage in response to plasmin.
PEG with MW of 2, 5, and 7 kDa was reacted with acryloyl chloride to produce
PEGDA as described [153]. Next, PEGDA in PBS was added dropwise to the solution of
SPCP peptide (PEGDA:SPCP molar ratio of 1:2.5) in acetonitrile/PBS (pH 7.4, 1 mM
TCEP) in a reaction flask with stirring and nitrogen flow. The reaction between the cysteine
groups of SPCP and acrylate groups of PEGDA was allowed to proceed for 6 h under
ambient condition. After the reaction, the PEG-SPCP conjugate was purified by dialysis
(500 Da MW cutoff membrane) against PBS and lyophilized (Figure 2.1b). Then, the
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carboxyl end-groups of PEG-SPCP conjugate were succinimide functionalized by reaction
with DSC as we previously described (Figure 2.1c) [126]. The chemical structure of the
lyophilized PEG-SPCP conjugate was characterized by 1H-NMR (Varian Mercury-300,
Palo Alto, CA) and FTIR (Perkin Elmer Spectrum 100, Waltham, MA) as described [126].
The functionalized conjugates with and without the plasmin-cleavable peptide are hereafter
referred to as PxSPCP and PxSP, respectively, where the letter “x” is the PEG MW in kDa,
“SP” is for the self-assembled peptide FFF, and “CP” is for the plasmin-cleavable peptide
KFKT.
To form NPs, the functionalized PxSPCP conjugates were dissolved in DMSO and selfassembled by dialysis against PBS. The NP suspension was freeze-dried to produce a freeflowing powder (Figure 2.1d). The average particle size, size distribution, and zeta
potential of PxSPCP NPs were measured with a Zetasizer dynamic light scattering (Nano
ZS, Malvern Instruments, Malvern, UK) at 25°C in Nano-pure water (Millipore, Billerica,
MA) as described.[4] To observe particle shape, 20 μL of the suspension was deposited
onto a 300-mesh carbon-coated copper grid and imaged with a transmission electron
microscope (Hitachi H8000, Schaumburg, IL).
2.2.3 Cell Culture. Human MSCs (Lonza, Allendale, NJ) were cultured in basal MSC
medium (high-glucose DMEM supplemented with 10% FBS, 100 units/mL penicillin and
100 µg/mL streptomycin) at a seeding density of 5000 cells/cm2 as we previously described
[137]. Human ECFCs (Boston Children Hospital) were cultured on 1% gelatin-coated
flasks in basal ECFC medium (Bluekit EBM-2 medium supplemented with 20% FBS) at a
density of 6500 cells/cm2 as described [147].
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2.2.4 Cell Encapsulation in LPELA and GelMA Hydrogels. The LPELA precursor
solution was prepared by mixing 200 mg LPELA, 4 mg Ac-GRGD cell-adhesive peptide
(2% by weight of LPELA) and 1.5 mg photo-initiator (0.75 wt%) in 1 mL PBS. After
sterilization by filtration, hMSCs at a density of 2×106 cells/mL were added to the sterile
LPELA solution, the suspension was injected between two sterile glass slides separated by
a spacer and crosslinked by UV irradiation as we described previously [4, 149]. The
GelMA precursor solution was prepared by mixing 50 mg GelMA and 0.375 mg photoinitiator (0.75 wt%) in 1 mL PBS. After sterilization by filtration, a 50:50 mixture of
hMSCs+ECFCs at a total density of 2×106 cells/mL were added to the sterile GelMA
solution, injected between two sterile glass slides separated by a spacer and crosslinked by
UV irradiation as we previously described [4]. After washing with PBS, the cellencapsulated LEPLA or GelMA hydrogels were cultured in the appropriate medium for
osteogenic or vasculogenic differentiation, respectively.
2.2.5 Grafting BMP2 to PxSPCP NPs and Protein Release. BSA was grafted to PxSPCP
NPs for particle size analysis, grafting efficiency and protein stability studies whereas
BMP2 was grafted for protein release and cell culture experiments. For grafting, 10 mg
PxSPCP NPs were dispersed in PBS by sonication for 5 min. Next, 0.5 mL of BMP2 (400
ng/mL) or BSA (20 mg/mL) were added to the NP suspension and the grafting reaction
between the free amine groups of BMP2 or BSA and the succinimide groups of the NPs
was allowed to proceed overnight under ambient condition as we previously described to
produce BMP2-PxSPCP NPs (Figure 2.1e) [4]. After the reaction, the suspension was
centrifuged at 15000 rpm for 10 min and the amount of free (not grafted) BMP2 or BSA in
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the supernatant was quantiﬁed by ELISA or BCA protein assay, respectively, as we
previously described [126].
For release studies, plasmin (0.2 U/mL) was added to the suspension of 10 mg BMP2PxSPCP NPs in 1 mL PBS and incubated at 37°C with shaking at 50 rpm. At each time
point, the suspension was centrifuged at 10,000 rpm for 5 min, the supernatant containing
the free BMP2 was collected and replaced with fresh plasmin solution. BMP2 content of
the supernatant solution was measured with a BMP2 ELISA kit as we previously described
[4]. BMP2 added directly to the plasmin solution and BMP2-PxSP NPs were used as
control groups.
2.2.6 Bioactivity and Cell Compatibility of BMP2-PxSPCP NPs. Circular dichroism
(CD) was used to determine the effect of grafting on the secondary structure of the model
BSA protein. CD spectra of free or grafted BSA in PBS were collected with a
spectropolarimeter (JASCO J815, Essex, UK) at 20°C with a cuvette of 0.1 cm path length
as we previously described [154] For evaluation of cell compatibility, hMSCs (1×106
cells/mL) and PxSPCP NPs (10 mg) were encapsulated in LPELA hydrogel as described
in section 2.5 and cultured in basal medium. At each time point, the hydrogels were stained
with cAM/EthD live/dead assay (1 μg/mL) and the stained cells were imaged with an
inverted fluorescent microscope (Nikon Eclipse Ti-ε, Nikon, Melville, NY) as described
[149]. To quantify cell viability, the medium was replaced with fresh medium containing
10% MTS and incubated for 6 h at 37oC and the sample absorbance was measured with a
microplate reader (Molecular Devices, San Jose, CA) at a wavelength of 490 nm.
The bioactivity of BMP2 released from the NPs was determined by measuring the
expression of osteogenic markers for hMSCs encapsulated in LPELA hydrogel and
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incubated in the osteogenic medium (without BMP2 or DEX) supplemented with BMP2
released from the NPs. The measured markers of osteogenic differentiation included Runx2
(early marker) and calcium (late marker). Control groups included hMSCs encapsulated in
LPELA hydrogel and incubated in osteogenic medium with or without BMP2 directly
added to the medium.
2.2.7 Measurement of Protease Expression of Encapsulated hMSCs and ECFCs.
hMSCs at a density of 2×106 cells/mL were encapsulated in LPELA hydrogel whereas
ECFCs or a 50:50 mixture of hMSCs+ECFCs at a total density of 2×106 cells/mL were
encapsulated in GelMA hydrogel as described in section 2.5. After gelation, disk-shape
samples were cut from the gels and incubated in the appropriate medium for up to 7 days.
hMSCs encapsulated in LPELA was cultured in osteogenic medium whereas ECFCs or
hMSCs+ECFCs in GelMA were cultured in vasculogenic medium. At each time point,
samples were divided into two parts for analysis. One part was used for measurement of
differential RNA expression of plasminogen, uPA, tPA, matrix metalloproteinase-2
(MMP2), and membrane-type matrix metalloproteinase-1 (MT-MMP1) by real-time
polymerase chain reaction (RT-qPCR) as we previously described [150, 155]. The genespecific primers for RT-qPCR were designed and selected using the Primer3 web-based
software as described [155]. The forward and reverse primers, synthesized by Integrated
DNA Technologies (Coralville, IA), are listed in Table 1. The expression of GAPDH
house-keeping gene was used as a reference and the model of Pfaffl was used to determine
the expression ratio of the genes as described [156]. The other part was used to quantify
protein expression of the total plasmin and MMP-2 in the intracellular and extracellular
compartments as well as the extracellular expression of bFGF. To quantify the extracellular
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expressions, the medium of the hydrogel cultures was centrifuged at 15000 rpm for 10 min
to separate the insoluble residue, the supernatant was concentrated 5-fold using a 10 kDa
cutoff membrane, and the protein concentration was measured by ELISA as we previously
described [4]. To quantify the intracellular expressions, the hydrogel sample was washed,
digested in RIPA buffer, centrifuged at 15000 rpm for 15 min, and the concentration of
proteins in the supernatant was measured by ELISA as described [4].
2.2.8 Encapsulation of hMSCs and ECFCs in Patterned Constructs. Patterned
hydrogel constructs with GelMA micro-channels in LPELA matrix were generated for coculture experiments as we previously described (Figure 2.2) [4]. Needles with a diameter
of 400 µm and inter-needle separation of 500 µm were inserted through the end-caps of a
cylindrical Teflon mold with a diameter and height of 5 and 3 mm, respectively (Figure
2.2a). Next, the sterile LPELA precursor suspension composed of 200 mg LPELA, 4 mg
Ac-GRGD cell-adhesive peptide, 1.5 mg photo-initiator, 20 mg plasmin-cleavable PxSPCP
NPs, and 2x106 hMSCs in 1 mL PBS was injected in the cylindrical mold and crosslinked
by UV irradiation as we previously described (Figure 2.2b) [66]. Then, the needles were
removed from the LPELA matrix and the sterile GelMA precursor suspension composed
of 50 mg GelMA, 0.375 mg photo-initiator, 2 mg VEGF-NGs, 2×106 of 50:50
hMSCs+ECFCs was injected in the channels and crosslinked by UV irradiation as
described (Figure 2.2c) [4]. After gelation, the patterned hydrogel constructs were washed
with warm PBS, cultured in basal medium for one day followed by cultivation in
vasculogenic medium (without VEGF) for days 2-7, 50:50 mixture of vasculogenic and
osteogenic medium (without VEGF, BMP2 or DEX) for days 8-10, and finally in
osteogenic medium (without DEX or BMP2) for days 11-21.
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2.2.9 Biochemical, mRNA and Protein Analysis, and Immunofluorescent Staining. At
each time point after washing the hydrogel constructs to remove serum proteins and
sonicating to lyse the encapsulated cells [157], the samples were divided into four groups
for biochemical, mRNA and protein analysis, and immunofluorescent staining. For
biochemical analysis, the double-stranded DNA content, ALP activity and calcium content
of the homogenized samples were measured as we previously described [157]. For mRNA
expression, the RNA of the homogenized samples was extracted and used for measurement
of mRNA expression of osteogenic markers (Runx2, Col I and ALP) and vasculogenic
markers (vWF, VEGFR, VE-cadherin, and CD31) as we previously described [4]. The
designed primer sequences for mRNA marker expression are listed in reference [4]. To
compare expression between the groups, mRNA fold difference for expression of the gene
of interest was normalized to that of GAPDH followed by normalization against day one
expression as described [157]. The expression of CD31 vasculogenic marker of the
homogenized samples at the protein level was quantified by western blot as we previously
described [4] Alizarin red and immunofluorescent staining were used to image the intensity
of mineralization and CD31 expression as we previously described [158, 159]. The stained
samples were imaged with a Nikon Eclipse Ti-ε inverted fluorescent microscope.
2.2.10 Statistical Analysis. All experiments were done in triplicate. Significant differences
between experimental groups were evaluated using a two-way ANOVA with replication
test, followed by a two-tailed Student’s t test. A value of p < 0.05 was considered
statistically significant.
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2.3. Results
2.3.1 Temporal Expression of Proteases by the Encapsulated hMSCs and ECFCs. The
mRNA expressions of uPA, tPA, and plasminogen in the fibrinolytic cascade for the
LPELA encapsulated MSCs, GelMA encapsulated ECFCs, and GelMA encapsulated
MSCs+ECFCs with incubation time are shown in Figures 2.3a, 2.3b and 2.3c, respectively;
the mRNA expressions of MMP2 and MT-MMP1 for the encapsulated MSCs, ECFCs, and
MSCs+ECFCs are shown in Figures 2.3d, 2.3e and 2.3f, respectively. The encapsulated
hMSCs expressed significant levels of uPA, tPA, plasminogen, MMP2 and MT-MMP1 in
osteogenic medium (days 1, 4 and 7) as shown in figures 2.3a and 2.3d. The expression of
uPA by MSCs did not change with differentiation in osteogenic medium whereas that of
tPA decreased, those of plasminogen and MMP2 increased, and that of MT-MMP1 peaked
on day 4. The encapsulated ECFCs did not express significant levels of proteases of the
fibrinolytic cascade and the expressions did not change with differentiation in vasculogenic
medium (Figures 2.3b and 2.3e). The encapsulated hMSCs+ECFCs expressed significant
levels of tPA and plasminogen with differentiation in vasculogenic medium but did not
express uPA, MMP2 and MT-MMP1. The expression of tPA of hMSCs+ECFCs peaked
on day 4 whereas that of plasminogen increased slightly with differentiation in the
vasculogenic medium.
Based on mRNA results, the extra- and intra-cellular expressions of plasmin and
MMP2, as well as extracellular expression of bFGF for the encapsulated hMSCs, ECFCs,
and hMSCs+ECFCs, were measured at the protein level and the expressions are shown in
Figure 2.4. For all cell types, the expressions of plasmin, MMP2 and bFGF increased with
cell differentiation. For all cell types, the extracellular expression of MMP2 was higher
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than the intracellular (Figures 2.4a and 2.4b) whereas the difference was not significant
for plasmin (Figures 2.4c and 2.4d). After 7 days of culture, the extracellular expression of
bFGF by the encapsulated hMSCs in osteogenic medium was higher than the ECFCs or
hMSCs+ECFCs in vasculogenic medium with hMSCs+ECFCs showing the lowest bFGF
expression (Figure 2.4e). Based on the results in Figures 2.3 and 2.4, the encapsulated
hMSCs showed higher expression of proteases with differentiation in osteogenic medium
as compared to ECFCs or hMSCs+ECFCs in vasculogenic medium. Therefore, BMP2 was
conjugated to plasmin-cleavable PxSPCP NPs and co-encapsulated with hMSCs in LPELA
hydrogel of the patterned matrix for on-demand release of BMP2 in response to plasmin
expression by hMSCs. As plasmin and MMP2 expression by the encapsulated
hMSCs+ECFCs was relatively low, VEGF was conjugated to hydrolytically-degradable
NGs and co-encapsulated with hMSCs+ECFCs in GelMA hydrogel of the patterned matrix
for release in the first 7 days to stimulate vasculogenic differentiation of the encapsulated
ECFCs in the channels.
2.3.2 Characterization of PxSPCP macromer. The mass spectra of CGGK(GFFFac)GGKFKTGG (SPCP, MW=1638.9 Da) and CGGK(GFFF-ac)GGG (SP, MW=1018.2
Da) peptides are shown in figure 2.6. In the SPCP spectrum (Figure 2S1a), m/z values of
820 and 1638 Da corresponded to the divalent [(M +2H)]2+ and monovalent [(M +H)]+
hydrogen cations of the peptide, respectively. In the SP spectrum (Figure 2.6c), m/z value
of 1018 Da corresponded to the monovalent [(M+H)]+ hydrogen cation of the peptide. The
HPLC chromatographs of SPCP and SP peptides are shown in the inset b and d of Figure
2S1, respectively. The retention times of SPCP and SP peptides were 10.1 (Figure 2.6b)
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11.0 (Figure 2,6d) min, respectively. The 1H-NMR spectra of PEGDA and PEG-SPCPNHS (PxSPCP) are shown in Supplementary Figure 2.7a.
Two chemical shifts with peak positions at 3.6 and 4.2 ppm in the spectrum of PEGDA
were attributed to the methylene hydrogens of PEG attached to ether and ester groups,
respectively; three chemical shifts with peak positions between 5.85-6.55 ppm were
attributed to vinyl hydrogens of the acrylate groups at chain ends as described [153] The
disappearance of chemical shifts for methylene protons (5.85-6.55 ppm) of the acrylate
groups in the spectrum of PxSPCP confirmed conjugation of the peptide to PEGDA.
Further, the appearance of a shift due to methylene hydrogens with a peak position at 2.77
ppm confirmed succinimide functionalization of PxSPCP. The FTIR spectra of PEGDA,
PEG-SPCP, and PEG-SPCP-NHS are shown in Supplementary Figure 2S2b. The
appearance of characteristic absorption bands in the spectra of PEG-SPCP and PEG-SPCPNHS with peak positions at 1630 and 3330 cm-1 due to vibrations of amides and secondary
amines, respectively, confirmed the conjugation of peptide to PEGDA. The appearance of
a characteristic band with peak position at 1779 cm-1 due to vibrations of NHS group
confirmed succinimide functionalization of PEG-SPCP-NHS.
2.3.3 Characterization of PxSPCP NPs. The number-average size distribution of
PxSPCP NPs with or without BSA protein grafting for PEG MW of 0.5, 2, 5 and 7.5 kDa
are shown in Figures 2.5a to 2.5d, respectively. The corresponding TEM images of the NPs
are shown in the inset of Figures 2.5a-d. The average particle size, polydispersity index
(PDI), and zeta potential of PxSPCP NPs as a function of PEG MW are listed in Table 1.
The average size of the NPs increased from 145±15 nm to 225±10, 265±20 and 325±25
nm as the PEG MW was increased from 0.5 kDa to 2, 5 and 7.5 kDa, respectively. The size
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distribution of the NPs was relatively narrow and increased with PEG MW. The average
size of P0.5SPCP NPs increased slightly after BSA grafting and the size increase with BSA
grafting increased with PEG MW.
The effect of incubation time in basal culture medium on the average size and size
distribution for different PEG MW of PxSPCP NPs is shown in Figures 2.6a and 2.6b,
respectively. For P0.5SPCP NPs, the hydrodynamic size increased significantly from 200
nm on day 1 to 500 nm on day 7 and PDI increased from 0.13 on day 1 to 0.38 on day 7
which was attributed to particle aggregation. For P2SPCP NPs, the average size increased
slightly from 225 nm on day 1 to 260 nm on day 7 and PDI did not change with incubation
time. For P5SPCP and P7.5SPCP NPs, the average size and PDI did not change with
incubation time. The results in Figures 2.6a and 2.6b indicated that P0.5SPCP NPs
aggregated in culture medium whereas P2SPCP, P5SPCP and P7.5SPCP were relatively
stable in culture medium with incubation. The effect of BSA grafting on the CD spectrum
of PxSPCP NPs as a function of PEG MW is shown in Figure 2.6c. The absorption
spectrum of BSA-P0.5SPCP NPs (red) was identical to that of free BSA whereas there was
a slight change in absorption spectrum of BSA-P2SPCP NPs (gold) in the 200-125 nm
region. The CD spectra of BSA-P5SPCP (dark blue) and BSA-P7.5SPCP (gray) were
substantially different from that of free BSA. Therefore, the conformational stability of the
grafted BSA decreased with increasing PEG MW of the NPs. Based on the CD results,
P0.5SPCP and P2SPCP maintained the secondary structure of grafted BSA whereas
P5SPCP and P7.5SPCP denatured the grafted protein. The effect of supplementing the
culture medium with PxSPCP NPs of different PEG MW on viability of hMSCs is shown
in Figure 2.6d. The viability of hMSCs decreased slightly with increasing PEG MW after
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3 days of incubation in basal medium. However, viability of hMSCs was >90% for all
PxSPCP NPs. As PEG2SPCP NPs had a relatively stable size distribution in culture
medium (Figures 2.6a and 2.6b), only a slight effect on the secondary structure of grafted
BSA (Figure 2.6c), and negligible toxicity toward hMSCs (Figure 2.6d), these NPs were
selected for vascularized osteogenesis experiments with hMSCs and ECFCs in the
patterned hydrogels.
2.3.4 Release Characteristics and Bioactivity of BMP2-PxSPCP NPs. The grafting
efficiency of BMP2 to PxSPCP NPs decreased from 73.1±2.7% to 69.5±3.2% and
24.5±1.4% as the PEG MW was increased from 2 kDa to 5 and 7.5 kDa, respectively. This
decrease was attributed to higher entrapment of the reactive succinimide groups of PxSPCP
within the NPs’ core with increasing PEG MW, which reduced their availability for BMP2
grafting. BMP2-PxSPCP NPs were encapsulated in LPELA hydrogel, the hydrogel was
incubated in PBS, and the release of BMP2 to the incubating medium was measured with
time by ELISA. Figures 2.7a to 2.7c show the release kinetic of BMP2 from the
encapsulated NPs in LPELA hydrogel with PxSPCP PEG MW of 2 (Figure 2.7a), 5 (Figure
2.7b) and 7.5 kDa (Figure 2.7c), respectively. Experimental groups included BMP2PxSPCP NPs plus plasmin encapsulated in the hydrogel (solid brown, solid gray or solid
blue in Figures 2.7a to 2.7c, respectively), BMP2-PxSP NPs plus plasmin in the hydrogel
(dash brown, dash gray or dash blue in Figures 2.7a to 2.7c, respectively), free BMP2 in
the hydrogel (red in Figures 7a-7c), and free BMP2 plus plasmin in the hydrogel (green in
Figures 2.7a-c). Approximately 80% of the loaded free BMP2 was released from the
hydrogel after 21 days of incubation and the addition of plasmin to the hydrogel did not
affect BMP2 release (compare red and green in Figures 2.7a-c). The incomplete (<100%)
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release of free BMP2 from the hydrogel was attributed to protein adsorption to the matrix
or protein denaturation during hydrogel encapsulation and gelation. ELISA measurements
detected a relatively small but significant BMP2 activity with incubation time for BMP2PxSP NPs and plasmin encapsulated in the hydrogel (see dash yellow, dash gray or dash
blue in Figures 2.7a-c) but the activity decreased with increasing PEG MW of the NPs. The
cumulative BMP2 activity after 21 days associated with the encapsulated BMP2-PxSP NPs
with PEG MW of 2, 5 and 7.5 kDa was 30%, 20% and 19% of the total BMP2 loaded in
the hydrogel, respectively. This BMP2 activity was attributed to the release of BMP2-PxSP
NPs from the hydrogel which was subsequently detected by ELISA. The BMP2 grafted to
PxSPCP NPs and co-encapsulated in the hydrogel with plasmin was gradually released to
the medium with incubation time at a rate faster than BMP2-PxSP NPs but slower than the
free BMP2. For example, the cumulative release of BMP2 from the encapsulated BMP2P5SPCP NPs was 60% after 21 days which was higher than the encapsulated P5SP NPs at
20% and slower than the free BMP2 at 80%. The results in Figure 2.7 demonstrate that
BMP2 was cleaved by plasmin from PxSPCP NPs, leading to the gradual release of the
protein from the hydrogel.
2.3.5 Osteogenic Activity of BMP2 Released from PxSPCP NPs. BMP2-PxSPCP NPs
(PEG MW of 2, 5 and 7.5 kDa) and hMSCs were co-encapsulated in LPELA hydrogel,
incubated in osteogenic medium without DEX, and the extent of osteogenesis was
measured with incubation time. The DNA contents of hMSCs with incubation time for
BMP2-PxSPCP NPs with PEG MW of 2, 5 and 7.5 kDa are shown in Figures 2.8a to 2.8c,
respectively; mRNA expressions of Runx2 are shown in Figures 2.8d to 2.8f; and ALP
mRNA expressions are shown in Figures 2.8g to 2.8i. Experimental groups included
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BMP2-P2SPCP NPs (solid brown), BMP2-P2SP NPs (dash brown), BMP2-P5SPCP NPs
(solid gray), BMP2-P5SPCP NPs (dash gray), BMP2-P7.5SPCP NPs (solid blue), and
BMP2-P7.5SP NPs (dash blue) co-encapsulated with hMSCs in LPELA hydrogel. Control
groups were hMSCs encapsulated in LPELA hydrogel and incubated in osteogenic medium
supplemented with (red) or without (purple) BMP2, and hMSCs co-encapsulated with
BMP2 in the hydrogel and incubated in osteogenic medium without DEX (green). The
DNA content of all groups decreased with incubation time. DNA content of those groups
incubated in osteogenic medium without BMP2 or with BMP2-PxSP NPs decreased at a
slower rate compared to those with BMP2 or BMP2-PxSPCP NPs, consistent with previous
reports [160, 161].
The expression of Runx2 increased initially from day 4 to 7 for all experimental groups,
peaked on day 7 followed by a decrease from day 7 to 14 for all BMP2-PxSPCP NPs
(Figures 2.8d to 2.8f). The osteogenic activity of the experimental groups was measured
by peak Runx2 expression of the encapsulated hMSCs. The osteogenic activity of the group
with BMP2 added to the medium was higher than the group with BMP2 co-encapsulated
with hMSCs in the hydrogel, which was attributed to denaturation of a small but significant
fraction of the encapsulated BMP2 during hydrogel formation. The osteogenic activity of
BMP2-PxSP NP groups (dash lines in Figures 2.8d-f) was similar to that of no BMP2 group
(purple in Figures 2.8d-f), demonstrating that BMP2 grafted to non-cleavable NPs had
negligible osteogenic activity. The BMP2-PxSPCP NP groups showed significantly higher
osteogenic activity compared to non-cleavable BMP2-PxSP NPs, thus confirming that a
significant fraction of BMP2 grafted to BMP2-PxSPCP NPs was cleaved by plasmin
secreted by the encapsulated cells. Further, osteogenic activity of BMP2-P2SPCP-NP and
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BMP2-P5SPCP-NP groups (solid brown in Figure 2.8d and solid gray in 8e) were similar
to that of free BMP2 added to the culture medium whereas that of BM2-P7.5SPCP-NP
group (solid blue in Figure 2.8f) was lower. This result was attributed to higher availability
of the plasmin-cleavable peptide in P2SPCP and P5SPCP NPs for enzymatic cleavage. The
peak Runx2 expression of hMSCs for BMP2-P2SPCP-NP and BMP2-P5SPCP-NP groups
was 5.7 which was significantly higher than BMP2-P7.5SPCP-NP at 4.2. ALP mRNA
expression of the encapsulated hMSCs peaked on day 14 for all experimental groups
(Figures 2.8g to 2.8i). Similar to Runx2 expressions, the peak ALP expression of the group
with BMP2 added to the medium was higher than the group with BMP2 co-encapsulated
with hMSCs in the hydrogel; peak ALP expression of BMP2-PxSP NP groups (dash lines
in Figures 2.8g-i) was similar to that of no BMP2 group (purple in Figures 2.8d-f); and
peak ALP expression of BMP2-PxSPCP NP groups was significantly higher than the noncleavable BMP2-PxSP NPs.The BMP2-P2SPCP-NP group (solid brown in Figure 2.8g)
had the highest peak ALP expression followed by BMP2-P5SPCP (solid gray in Figure
2.8h) with BMP2-P7.5SPCP (solid blue in Figure 2.8i) as the lowest. The peak ALP
expression of hMSCs for BMP2-P2SPCP-NP, BMP2-P5SPCP-NP and BMP2-P7.5SPCPNP groups was 60, 52 and 48, respectively. As P2SPCP NPs had the most stable size
distribution (Figures 2.6a-b), negligible loss of secondary structure of the grafted protein
(Figure 2.6c), and highest osteogenic activity of the grafted BMP2 (Figure 2.8), these NPs
were selected for co-culture experiments with hMSCs and ECFCs in the patterned
hydrogels.
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2.3.6 Osteogenic and Vasculogenic Differentiation of hMSCs and ECFCs in patterned
hydrogels with plasmin-cleavable BMP2-P2SPCP NPs. The effect of the on-demand
release of BMP2 from plasmin-cleavable NPs on osteogenesis to vasculogenesis was
investigated in patterned hydrogels consisting of GelMA microchannels encapsulating
hMSCs+ECFCs/VEGF-NGs in LPELA matrix encapsulating hMSCs/BMP2-P2SPCPNPs. The results are shown in Figures 2.9 through 2.12. All experimental groups were
cellular. The groups included patterned constructs with BMP2-P2SPCP-NP in LPELA
matrix and VEGF-NG in GelMA channels (BMP2-P2SPCP-NP/VEGF-NG, black); unpatterned constructs with BMP2-P2SPCP-NP+VEGF-NG in a mixture of LPELA+GelMA
with a composition identical to the patterned matrix (BMP2-P2SPCP-NP+VEGF-NG UnP,
dash gray); patterned constructs with BMP2-P2SPCP-NP in LPELA and GelMA channels
without VEGF (BMP2-P2SPCP-NP, green); patterned constructs with LPELA without
BMP2 and VEGF in GelMA channels (VEGF-NG, gold); patterned constructs with BMP2
in LPELA and VEGF in GelMA (BMP2/VEGF, red); patterned constructs without BMP2
or VEGF (None, light blue); and un-patterned constructs based on a mixture of
LPELA+GelMA with a composition identical to the patterned matrix without BMP2 or
VEGF (None UnP, brown).
The DNA content, calcium content, ALP activity, mRNA expression of osteogenic
markers Runx2, ALP, and Col I of the patterned cellular constructs are shown in Figure
2.9. The DNA content of all BMP2 or BMP2/VEGF groups (Figure 2.9a) decreased with
incubation time, consistent with previous reports [160, 161] For all groups, Runx2
expression (Figure 2.9b) of the encapsulated cells peaked on day 14 whereas Col I
expression (Figure 2.9d) and calcium content (Figure 2.9e) steadily increased with
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incubation time. For the NP groups, ALP activity peaked on day 18 (Figures 2.9c and 2.9f)
whereas it peaked on day 14 for the free BMP2/VEGF group. The groups with BMP2 and
VEGF (with or without grafting to NPs/NGs) had highest peak expression of osteogenic
markers Runx2 and ALP as well as highest Col I expression and calcium content on day
21. Among the groups with BMP2 and VEGF, the patterned BMP2-P2SPCP-NP/VEGFNG group had highest expression of osteogenic markers followed by the patterned
BMP2/VEGF, un-patterned BMP2-P2SPCP-NP+VEGF-NG, and patterned BMP2P2SPCP-NP groups. For example, the Col I fold expressions of patterned BMP2-P2SPCPNP/VEGF-NG, patterned BMP2/VEGF, un-patterned BMP2-P2SPCP-NP+VEGF-NG,
and patterned BMP2-P2SPCP-NP groups were 25, 20, 22 and 15, respectively (Figure
2.9d); the calcium contents were 770, 695, 665 and 390 mg/mg DNA (Figure 2.9e); and
ALP activities were 6600, 5000, 4850 and 2550 IU/mg DNA (Figure 2.9f). Interestingly,
the calcium content, ALP activity, and expression of osteogenic markers for patterned
BMP2-P2SPCP-NP group was significantly less than those of BMP2-P2SPCP-NP/VEGFNG, BMP2/VEGF and un-patterned BMP2-P2SPCP-NP+VEGF-NG groups. This finding
can be attributed to the lack of paracrine signaling between hMSCs and ECFCs in the
absence of VEGF-NGs. The images for Alizarin red staining of the patterned BMP2P2SPCP-NP/VEGF-NG, BMP2/VEGF and BMP2-P2SPC-NP groups are shown in Figure
2.10. The images show robust mineralization and nodule formation for these groups with
the patterned BMP2-P2SPCP-NP/VEGF-NG group showing the most intense staining.
The DNA content, mRNA expression of vasculogenic markers vWF, VEGFR and VEcadherin, and protein expression of CD31 vasculogenic marker of the patterned constructs
are shown in Figure 2.11. DNA content of the groups with BMP2/VEGF or VEGF only
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decreased with incubation time with differentiation of the encapsulated hMSCs and
ECFCs. The expression of vasculogenic markers for the groups with BMP2/VEGF or
VEGF only increased with incubation time whereas the expression for those groups
without BMP2 or VEGF did not change significantly. After 10 days of incubation, the
patterned BMP2-P2SPCP-NP/VEGF-NG group (black in Figure 2.11) had highest mRNA
expression of vasculogenic markers vWF, VEGFR, VE-cadherin and CD31 as well as
highest CD31 protein expression followed by the patterned BMP2/VEGF (red in Figure
2.11), un-patterned BMP2-P2SPCP-NP+VEGF-NG (gray in Figure 2.11) and patterned
VEGF-NG (gold in Figure 2.11) groups. For example, the normalized CD31 mRNA
expressions (Figure 2.11e) of the patterned BMP2-P2SPCP-NP/VEGF-NG, patterned
BMP2/VEGF, un-patterned BMP2-P2SPCP-NP+VEGF-NG and patterned VEGF-NG
groups were 100, 68, 60 and 28, respectively, and the normalized CD31 protein expressions
of those groups were 1.0, 0.96, 0.9 and 0.75. Similar to the osteogenic markers in Figure
2.9, the expression of vasculogenic markers for the patterned VEGF-NG group was
significantly

less

than

the

patterned

BMP2-P2SPCP-NP/VEGF-NG,

patterned

BMP2/VEG and un-patterned BMP2-P2SPCP-NP+VEGF-NG groups. The fluorescent
images for CD31 immunostaining of the patterned BMP2-P2SPCP-NP/VEGF-NG,
BMP2/VEGF, and VEGF-NG groups are shown in Figure 2.12. The images show robust
vascularization for the patterned BMP2-P2SPCP-NP/VEGF-NG as well as BMP2/VEGF
groups.
2.4. Discussion
Peptide-based nanomaterials, due to their versatility, are very attractive as a cellresponsive morphogen delivery system in tissue engineering [162] In this work, we
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designed a peptide-PEG macromer composed of a phenylalanine sequence for selfassembly and a plasmin-cleavable sequence for BMP2 release in response to plasmin
secretion by MSCs and ECFCs. The hydrophilic PEG block of the hybrid macromer
provided stability in physiological medium while the hydrophobic phenylalanine sequence
induced self-assembly into core-shell NPs with the peptides in the core and the PEGs in
the hydrated corona [163, 164] The measured zeta potential of P0.5SPCP NPs (−11.2 mv)
was lower than the reported value for the triblock poly(ethylene glycol)-b-poly(L-glutamic
acid)-b-poly(L-phenylalanine) (PEG-b-PGlu-b-PPhe) nanogels at -20 mv [142] The
measured zeta potentials of PxSPCP NPs (x=2, 5, and 7.5 kDa) were higher than the
reported values for PEG-b-PGlu-b-PPhe nanogels and the amphiphilic Arg−His3−Phe4
oligo-peptide RH3F4 (−2.5 mv) [142, 165] These results was attributed to the existence of
negatively-charged carboxyl groups in the corona of PxSPCP NPs [165]
The CD spectrum of BSA-PxSPCP NPs in Figure 2.6c showed progressively larger
deviation from that of ungrafted BSA with increasing PEG MW. The CD spectrum of BSAPEG0.5SPCP NPs with PEG MW of 500 Da was identical to that of ungrafted BSA
whereas the spectrum of BSA-PEG2SPCP NPs with PEG MW of 2 kDa was slightly
different in the 200-215 nm range. On the other hand, the spectra of BSA-PEG5SPCP and
BSA-PEG7.5SPCP NPs with 5 and 7.5 kDa PEG MW deviated significantly from that of
ungrafted BSA. This deviation was attributed to greater segregation of the peptide and PEG
blocks into the core and corona of the NPs, respectively, with increasing PEG MW. As the
succinimide group used for BSA grafting is hydrophobic, the grafted BSA would increase
be associated with the hydrophobic core with increasing PEG MW, leading to greater loss
of BSA secondary structure and denaturation of the protein. The increase in the
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hydrodynamic size of PEG0.5SPCP NPs in aqueous solution (Figure 2.6a and 2.6b) with
incubation time was attributed to the imbalance of hydrophobicity and hydrophilicity of
the PEG-peptide macromer which led to aggregation of the NPs in aqueous medium. The
release kinetic of BMP2 from BMP2-PxSPCP NPs decreased with increasing PEG MW
(Figures 2.7a-c). This decrease was attributed to the increased segregation of the peptide
and PEG blocks of PxSPCP macromer into the core and corona of the NPs, respectively,
leading to greater entrapment of the plasmin-cleavable peptide in the core of the NPs, and
decreased availability of plasmin to the peptide. Further, the longer PEG chains on the NPs’
corona increased the entropically-driven compression energy required for diffusion of
plasmin in the corona layer, which in turn reduced the release of BMP2 from the NPs [166,
167].
The hMSC/ECFC co-culture results in patterned constructs (Figures 2.9-12)
demonstrate that the on-demand release of BMP2 from plasmin-cleavable PxSPCP NPs
enhanced osteogenesis and vasculogenesis compared to the direct addition of BMP2. The
enhancement can be attributed to the release of BMP2 from PxSPCP NPs in response to
enzymes secreted by the encapsulated hMSCs and ECFCs, particularly uPA, tPA,
plasminogen, MMP2 and MT-MMP enzymes. The measured enzyme secretions of MSCs
and ECFCs in Figures 2.3 and 2.4 are consistent with the results from previous reports
[134, 168, 169] Further, co-cultures of MSCs and ECFCs are known to stimulate capillary
morphogenesis by secreting MMPs and plasminogen [170] The enhancement in
osteogenesis/vasculogenesis observed in Figures 2.9-12 with on-demand release of BMP2
can be attributed to a) release of VEGF from VEGF-NGs in the first 5 days of culture to
differentiate ECFCs to the endothelial lineage, b) secretion of proteolytic factors like
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MMPs, plasminogen, tPA, and bFGF by the endothelial cells, c) diffusion of the proteolytic
factors from the microchannels to the matrix, d) cleavage of the plasmin-cleavable peptide
in BMP2-PxSPCP NPs by the diffused proteolytic factors leading to the release of BMP2,
e) osteogenic differentiation of hMSCs by the released BMP2, and f) secretion of
proteolytic and vasculogenic factors by the differentiated hMSCs. These events led to the
coupling of growth factor release by the differentiated hMSCs and ECFCs which enhanced
osteogenesis and vasculogenesis.
The results of this work show that hMSCs and ECFCs encapsulated in a patterned
composite hydrogel release proteolytic factors like MMPs, plasminogen and tPA as well
as others and that the released factors are able to cleave plasmin-degradable peptides
embedded in PxSPCP NPs to release morphogens like BMP2 on-demand. The results
further show that the on-demand release of BMP2 leads to a coupling of paracrine signaling
between the differentiating hMSCs and ECFCs. The on-demand release of BMP2 from the
NPs in response to secretions of MSCs/ECFCs not only enhances osteogenesis and
vasculogenesis but it has the potential to reduce many undesired side-effects of BMP2
therapy in bone regeneration [171]
2.5 Conclusion
Bifunctional, hybrid PEG-peptide PxSPCP NPs with a triphenylalanine (FFF) selfassembly peptide and a lysine-phenylalanine-threonine-lysine (KFTK) plasmin-cleavable
peptide are developed in this work for the on-demand release of BMP2 in response to
proteolytic factors secreted by the differentiating hMSCs and ECFCs encapsulated in a
patterned hydrogel construct. The hMSCs and BMP2-PxSPCP NPs were encapsulated in
the matrix whereas hMSCs+ECFCs and VEGF-NGs were encapsulated in the
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microchannels of the patterned construct. The PxSPCP NPs had a core-corona morphology
with the self-assembling peptides in the core and PEGs in the corona. The stability of NPs
in aqueous solution and the BMP2 stability against denaturation was a strong function of
PEG MW. The P2SPCP NPs with PEG MW of 2 kDa showed the most stable particle size
distribution and protein secondary structure with incubation. The BMP2 grafted to P2SPCP
NPs and co-encapsulated in SPELA hydrogel with plasmin was gradually released to the
medium with incubation time at a rate faster than the non-cleavable BMP2-PxSP NPs but
slower than the free BMP2. Further, the released BMP2 from the NPs by the action of
plasmin induced differentiation of hMSCs encapsulated in the LPELA hydrogel. The ondemand release of BMP2 from P2SPCP NPs in the patterned constructs in response to
proteolytic factors like MMPs, plasminogen and tPA as well as others secreted by the
encapsulated cells led to highest extent of osteogenesis and vasculogenesis and coupling
of paracrine signaling between the differentiating hMSCs and ECFCs. The on-demand,
cell-triggered release of BMP2 is a promising strategy for promoting vascularized
osteogenesis and reducing many undesired side-effects of BMP2 therapy in regeneration
of skeletal tissues.
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Table 2.1. The forward and reverse sequences for PCR primers

Table 2.2 Average size, distribution, zeta potential, and grafting efficiency of PxSPCP NPs
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Figure 2.1. Schematic diagram for the synthesis of plasmin-cleavable, self-assembled, BMP2-grafted PxSPCP NP.
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NP-BMP2

NP-VEGF

NP-VEGF

Figure 2.2. Schematic diagram for generating the patterned, cellular constructs. The LPELA hydrogel precursor solution loaded with
hMSCs and BMP2-PxSPCP NPs was injected inside a Teflon cylinder fitted with needles. After LPELA gelation, needles were removed
and the GelMA precursor solution loaded with ECFCs+hMSCs and VEGF-NGs was injected in the microchannels and crosslinked. The
constructs were cultured in appropriate medium with time and analyzed with respect to the expression of markers for osteogenesis and
vasculogenesis.
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1.

Figure 2.3 Schemes showing chemical structures of linear polyethylene glycol (LPELA) macromer (a), polyethylene glycol diacrylate
(PEGDA, b), plasmin-cleavable, self-assembling peptide (SPCP, b), SPCP-PEG conjugate (c), and succinimide-functionalized SPCPPEG conjugate (PxSPCP, d). Schematic diagram showing the self-assembly of PxSPCP to form NPs (e) and grafting of BMP2 to
PxSPCP NPs (f)
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Figure 2.4 Messenger RNA expressions of fibrinolytic genes (uPA, tPA and plasminogen)
and MMPs (MMP-2 and MT-MMP1) of the unpatterend and patterned construvts for (a
and d)- MSCs in osteogenic media (b,e)- ECFCs in vasculogenic media and (c,f)MSCs/ECFCs in vasculogenic media in pattern matrices, respectively.
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Figure 2.5 Extra- and intracellular protein expressions of total plasmin and MMP-2 as well
as extracellular bFGF of the unpatterned and patterned constructs (a-e). Groups included
unpatterend MSCs in osteogenic media (purple)- Unpatternd ECFCs in vasculogenic media
(green), and patterned MSCs/ECFCs in vasculogenic media (red), respectively.
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Figure 2.6 Mass spectra and the RP-HPLC chromatogram of G2KTFKGG-K(AcFFFG)G2C (SPCP, a-b) and G2-K(Ac-FFFG)G2C (SP, c-d).

Figure 2.7 1H-NMR spectra of polyethylene glycol diacrylate (PEGDA) and succinimideterminated suc-SPCP-PEG conjugate showing the assignment of all peaks and their
corresponding chemical structures in the macromers.
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Figure 2.8 Dynamic light scattering analysis (DLS) of the effect of PEG MW on PxSPCP
NPs size distribution. PxSPCP NPs (solid lines) and BSA grafted PxSPCP NPs (dashed
lines). The abbreviations PxSPCP represent NPs with x = 0.5, 2, 5, and 7.5 kDa PEG MW,
SP and CP represent NPs with self-assemble and cleavable peptides, respectively.
Morphology of the dried NPs is shown in the inset SEM images in (a–d). Scale bar
represents 200 nm.
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Figure 2.9 Average particle size and polydispersity index (PDI) of PxSPCP nanoparticles
in stability tracking from Dynamic light scattering analysis (a and b). Circular dichroism
(CD) spectra of free BSA and BSA grafted PxSPCP NPs (c). Viability of PxSPCP on
hMSCs using Celltiter-96 (MTS) assay (d). Error bars correspond to means ± 1 SD for n=3.
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Figure 2.10 Fluorescence images of live (green) and dead (red) staining of hMSCs
encapsulated in LPELA hydrogel along with PxSPCP (x=3, 5, and 7.5 kDa) after 1 and 3
days of incubation (a-h). Scale bar of 100 um.
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Figure 2.11: The release kinetics of BMP2 grafted to P2SPCP, P2SP, P5SPCP, P5SP,
P7.5SPCP and P7.5SP NPs, respectively, encapsulated in LPELA hydrogel, in response to
exogenous plasmin (+). The figure also shows the release kinetics of free BMP2 (-, solid
green) and free BMP2 with plasmin (+, solid red), respectively. The cumulative release of
BMP2 was measured by Enzyme-Linked Immunosorbent Assay (a-c) Error bars
correspond to means ± 1 SD for n=3.
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Figure 2.12: The Osteogenic activity of plasmin-cleavable BMP2 on hMSCs encapsulated
in LPELA hydrogel. DNA content (a-c), and mRNA expression of osteogenic markers
Runx2 (d-f) and ALP (g-i) for hMSCs encapsulated in LPELA. Groups included constructs
without BMP2 (solid purple), with free BMP2 in media (solid red), with encapsulated
BMP2 (solid green), with PxSPCP-BMP2 (solid brown for x=2; solid gray for x=5; and
solid blue for x=7.5 kDa); and with PxSP-BMP2 (dashed brown for x=2; dashed gray for
x=5; and dashed blue for x=7.5 kDa). Constructs were incubated in osteogenic medium for
21 days (without BMP2, or DEX).
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Figure 2.13: DNA content (a), mRNA expression of osteogenic markers Runx2 (b),
ALPase (c), Col I (d) and calcium content (e), ALPase activity (f) for hMSCs and ECFCs
encapsulated in the patterned and constructs. Groups included patterned constructs without
VEGF/BMP2 (solid blue), with VEGF/BMP2 (solid red), with NP-BMP2 (solid green),
and with NG-VEGF/NP-BMP2 (solid black); unpatterned osteogenic constructs with NGVEGF/NP-BMP2 (dashed gray) and without VEGF/BMP2 (dashed light blue). Constructs
were incubated in vasculogenic medium for 7 days, vasculogenic/osteogenic medium for
3 days, and osteogenic medium for 11 days (without VEGF, BMP2, or DEX). “An asterisk”
represents a statistically significant difference in the ordinate between the test and None
groups for the same time point. “An asterisk” represents a statistically significant difference
between the test and None groups for the same time point; “Two asterisks” represents a
significant difference between the test group and patterned construct with VEGF/BMP2.
Error bars correspond to means ± 1 SD for n=3.
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Figure 2.14 Alizarin red stained images of the constructs of a patterned microchannel with
NP/NG-grafted BMP2/VEGF, directly added BMP2/VEGF and patterned NP-grafted
BMP2 only, after 21 days of incubation. The top images show Alizarin red staining the top
of the channel while the bottom images show Alizarin red staining along the length of a
microchannel. Scale bar is 500 um.
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Figure 2.15 DNA content (a), mRNA expression of vasculogenic markers vWF (b),
VEGFR (c), VE-cadherin (d), CD31 (e), and CD31 protein expression (f) and
representative western blot bands (g) for hMSCs and ECFCs encapsulated in the patterned
and unpatterned constructs. Groups included patterned constructs without VEGF/BMP2
(blue), with VEGF/BMP2 (red), NG-VEGF (golden) and with NG-VEGF/NP-BMP2
(black); unpatterned vasculogenic constructs with NG-VEGF/NP-BMP2 (gray) and
without VEGF/BMP2 (light blue). “An asterisk” represents a statistically significant
difference in the ordinate between the test and None groups for the same time point.
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Figure 2.16 Fluorescence images of CD31 expression stained (green) of the microchannel
patterned constructs with NG-VEGF/NP-BMP2, VEGF/BMP2, and patterned NG-VEGF
after 7 days of incubation. The top images show CD31 staining the top of the channel while
the bottom images show CD31 staining along the length of a microchannel. Scale bar is
500 um.
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CHAPTER 3: SYNTHESIS AND CHARACTERIZATION OF
PHOTO-CROSS LINKABLE SERICIN HYDROGELS FOR STEM
CELLS ENCAPSULATION
3.1 Introduction
Natural hydrogels have been widely used as a 3D matrix for delivery and
immobilization of stem cells in soft tissue regeneration owing to its resemblance to natural
extracellular matrix (ECM) as they provide biocompatibility, biodegradability, and natural
cell binding sites [172]. In-situ-forming hydrogels have been known as promising
biomaterials in tissue repairing applications because their pre-gel solutions can be injected
into the damaged site through minimally invasive surgical procedures and ﬁll irregular
shape defects before gelation [173]. Among various starting biomaterials, sericin and
fibroin, the silk main proteins, have become the topic of research in tissue engineering with
various forms of cell delivery systems, such as films, scaffolds and hydrogels due to its
excellent biocompatibility, biodegradability and valuable bioactivities [174, 175]. Silk
industry is the major source of sericin that produces as a by-product around 50K tons
annually. However, such sericin was degraded (sericindegraded) because of the harshness
extraction method used in the degumming process. The sericindegraded was hard to
crosslinked in the form of hydrogels to be used in tissue engineering applications [176].
Instead, sericindegraded was used to form cross-linkable, composite hydrogels with other
polymers by biotoxic crosslinkers leading to losing some of the sericin’s natural
bioactivities [176]. Sericin is a family of “gluelike” proteins produced in nature by the
silkworm as a 20-30 % of total cocoon weight [177]. It is highly hydrophilic with a
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molecular weight that ranges from 20 to 400 kDa and consists of 32% of serine and 18
amino acids, including essentials [178]. Structurally, silk sericin is a globular protein
consisting of random coil and β-sheets [178, 179]. Because of its biocompatibility,
biodegradability and bioactivities, sericin has been increasingly used to synthesize various
types of cell delivery systems, such as scaffolds films, and hydrogels in anticipating of
repairing tissues [174, 175]. Silk sericin is shown to accelerate several mammalian cell
lines proliferation and attachment [180] such as keratinocytes, fibroblasts, epithelial cells
and osteoblasts[181]. Further, sericin was used for bone tissue engineering regarding its
ability to promote nucleation of bone-like hydroxyapatite [175]. Sericin hydrogels have
been developed that could be formed under physiological conditions, and the structure of
sericin can be chemically modiﬁed through its hydroxyl, amino, and carboxyl groups to
control the properties of the resulting biomaterials. A 3D sericin gel has been synthesized
that it is an injectable material, promotes cell adhesion and long-term survival, and
possesses multiple physical and chemical properties that provide a sustained drug release
ability, which can be tailored and customized to different tissue repair applications, serving
as a multifunctional platform for cell therapy [182].
In this study, sericin was extracted from silk cocoon and modiﬁed with
isocyanatoethyl methacrylate to form urethane methacrylated sericin (SerAte), Figure 3.1.
Ultraviolet light was used to cross-link the in situ SerAte hydrogels by the free radical
polymerization reaction. The physical properties of the SerAte hydrogels were
characterized. Cells attachment and proliferation were observed when the hMSCs were
cultured in the SerAte hydrogels. The final goal of this study is to develop the in situ SerAte
hydrogels for encapsulation and delivery of stem cells in tissue regeneration.
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3.2 Materials and Methods
Materials. Silk Cocoons was obtained from the Yarn Tree USA Company (Greenville,
Sc). Diethyl ether, citric acid, lithium chloride, and isocyanatoethyl methacrylate (IEM)
were purchased from VWR (Bristol, CT). Streptomycin, L-proline, ascorbic acid, sodium
pyruvate, and β-glycerol phosphate were purchased from Sigma-Aldrich (St. Louis, MO).
Dexamethasone (DEX) were purchased from Lonza (Hopkinton, MA). Phosphate-buffer
saline (PBS) and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from
GIBCO BRL (Grand Island, NY). Trypsin and fetal bovine serum (FBS) were received
from Invitrogen (Carlsbad, CA) and Atlas Biologicals (Fort Collins, CO), respectively.
Collagenase type 3 was purchased from Worthington (Lakewood, NJ). TRITC-conjugated
Phalloidin and 4,6-diamidino-2-phenylindole (DAPI) were purchased from EMD
Millipore (Billerica, MA). The Live and Dead calcein-AM (cAM) and ethidium
homodimer-1 (EthD) cell viability/cytotoxicity kit was purchased from Molecular Probes
(Life Technologies, Grand Island, NY). The dialysis tubes with molecular weight (MW)
cutoff of 3.5 kDa was purchased from Spectrum Laboratories (Rancho Dominquez, CA).
Bovine serum albumin (BSA) was received from Jackson ImmunoResearch (West Grove,
PA). Trichrome collagen staining
3.2.1 Extraction of Sericin from Cocoons. Silk cocoons were cleaned by soaking in ether
followed by washing with soap water. The cleaned cocoons were dried and chopped into
small pieces. Nine grams of the chopped cocoons were boiled for 30 mins in 160 mL of
1.25% citric acid to prepare the aqueous sericin solution. Then, the solution was filtered
(paper filtration) and centrifuged at 4.4 rpm to remove insoluble fibers. The clear filtrate
was dialyzed immediately against deionized water for three days with a 3.5 kDa molecular
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weight cutoff dialysis tube at the ambient condition with a change of deionized water every
6 h. Finally, the dialyzed cocoon solution was lyophilized to dryness and stored at -20 oC.
3.2.2 Modiﬁcation of sericin and SerAte Hydrogel formation. SerAte was synthesized
following the literature protocol [183]. Brieﬂy, 1.0 g of extracted sericin, after vacuumdrying in oven at 50 °C for 24 h, was dissolved at 2 wt % in anhydrous LiCl/DMSO
solution at 60 °C for 45 min under nitrogen atmosphere, and isocyanatoethyl
methacrylate (IEM) of different folds molar excess (relative to the serine), as listed in Table
3.1, was added dropwise to the solution, and the reaction continued for 24 h. The product
was dialyzed against deionized water for at least 48 h, followed by centrifugation to remove
the precipitate, which was then ﬂash frozen in liquid nitrogen, and lyophilized, resulting in
a powder that was analyzed by the degree of modiﬁcation by 1H NMR. Introducing of
urethane methacryloly groups to the hydroxyl groups of sericin was to produce photocrosslinkable sericin methacryloyl (SerAte). When exposed to UV light, the sericin
methacryloyl (SerAte) solution was rapidly crosslinked in situ forming a sericin hydrogel
through photo-polymerization of methacryloyl groups. Urethane methacrylated SerAte is
expected to be the more hydrophilic end-group and decreased degradation time due to
possible hydrogen bonding between the urethane group and molecules of water as well as
increase the porosity and pore sizes.
3.2.3 Circular Dichroism. Circular Dichroism (CD) spectra were recorded using a JASCO
J815 spectropolarimeter (JASCO, Essex, UK) at room temperature. The sample was
prepared by dissolving the freeze-dried sericin and SerAte in deionized water at a
concentration of 0.1 mg/mL. Infrared (IR) spectrum of the sericin and SerAte samples as a
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powder was measured in a range of 650-4000 cm-1 using a Perkin Elmer 100 spectrometer
with an attenuated total reflection diamond cell attachment.
3.2.4 SDS Polyacrylamide Gel Electrophoresis. SDS-PAGE analysis was used to
determine the molecular weight of sericin before and after modification. Extracted sericin
and SerAte powders were dissolved in 2x sample buffer (BioRad, Hercules, CA) with 5%
2-mercaptoethanol. The proteins were separated using a vertical slab gel electrophoretic
system with a 4-20% stacking gel. Electrophoresis was performed at 100 V and 15 mA for
80 min. The proteins were stained with Biosafe Coomassie brilliant blue R-250 for 1h and
de-stained using DIH2O, according to supplier’s instructions.
3.2.5 Thermogravimetric Analysis. Thermogravimetric analysis (TGA) of the sericin and
SerAte was performed using a universal V4.4A thermogravimetric analyzer (TA
Instruments, New Castle, DE). Five mg of the samples in Al2O3 crucibles were heated from
30°C to 700°C at a rate of 10°C/min and sample weight was recorded with time.
3.2.6 Gelation and Rheological measurements. To study the gelation and mechanical
properties, the SerAte macromers have crosslinked in aqueous solution by UV free-radical
polymerization with Irgacure 2959 (CIBA, Tarrytown, NY) photoinitiator as described
[184]. Briefly, the SerAte macromer was dissolved in the initiator solution vortexed and
loaded on the Peltier plate of the rheometer (TA Instruments AR-2000, New Castle, DE)
to measure the gelation time. A 20 mm plate acrylic geometry was used at a gap distance
of 500 µm. A sinusoidal shear strain with the frequency of 1 Hz and 1% strain was applied
on the sample while the sample was irradiated with a BLAK-RAY 100-W mercury longwavelength (365 nm) UV lamp (Model B100-AP; UVP, Upland, CA). The storage (G’)
and loss moduli (G”) of the samples were recorded with irradiation time. The time at which
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the storage (G’) equals loss modulus (G”) was recorded as the gelation time. To measure
the compressive modulus of the SerAte hydrogels, the precursor solutions were transferred
to a mold (polytetrafluoroethylene PTFE, 5 cm x 3cm x 750 nm) and the mold was covered
with transparent glass. Next, the samples were irradiated with UV for 3 min to complete
the crosslinking reaction. Samples with disk-shaped were cut from the hydrogel using
puncture, loaded on the Peltier plate and subjected to a uniaxial compressive force at a
displacement rate of 7.5 um/s. The slope of the linear matches to the stress-strain curve for
10% strain was taken as the compressive modulus, as described before [184].
3.2.7 Swelling Ratio and Stability Analysis. The swelling property of each hydrogel was
determined by the ﬁnal weight divided by the initial weight of the disk-shaped hydrogels.
The initial weights of hydrogels were recorded (Wi). Hydrogels were immersed in 2 mL
of PBS at room temperature, and then the weights after immersion over time were recorded
(Wt). Surrounding water was drained and blotted out with Whatman ﬁlter paper from
hydrogels before weighing. The swelling ratios were calculated from Wt/Wi. For the
stability test, the disk-shaped hydrogels were incubated with 2mL of PBS at room
temperature. The hydrogel mass reduction at each time point was monitored. The hydrogels
were collected, washed with DI water, and dried in vacuum for 2h at 40 Co before the dry
weight was measured. The dry weight at the starting point was measured as (Wd). The dry
weight measured at different time points was symbolized (Wt). Normalized hydrogel dry
weight was calculated as Wt/ Wd.
3.2.8 Scanning Electron Microscopy. The microstructure of the sericin hydrogels was
imaged using a VEGA3 SBU variable pressure scanning electron microscope (SEM;
Tescan, Kohoutovice, Czech Republic) at 8 keV accelerating voltage. The freeze-dried
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samples were immersed in liquid nitrogen and cut with a surgical blade to expose a freshly
cut surface. The surface was coated with gold using a Denton Desk II sputter coater
(Moorestown, NJ) at 20 mA for 75 s and imaged with SEM.
3.2.9 Potential biocompatibility and human MSCs adhesion on the SerAte hydrogel.
Human MSCs (Lonza, Allendale, NJ) were cultured in an α-MEM medium supplemented
with 16 % FBS, 3mM glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin
(basal medium). After reaching 70% confluency, the hMSC cells were detached with 0.1%
trypsin- 0.03% EDTA and sub-cultured at a ratio of 1:3 for <7 passages, according to
supplier’s instructions. Cell adhesion experiments were done with different hydrogels of
comparable compressive moduli. Twenty four well culture plates were coated with a thin
layer of 15, 17 and 20 wt% SerAte II, and crosslinked with UV to form the hydrogels.
Next, hMSCs were seeded on the surface of the gels at a density of 5x10 3 cells/cm2 and
cultured in basal medium for cell attachment. For immunofluorescent staining, wells were
washed twice in PBS and fixed with 4% paraformaldehyde (Sigma Aldrich) at 4°C for 30
min. Next, samples were permeabilized with 0.1% Triton X-100 and 100 mM glycine in
PBS for 15 min and blocked with 4 % BSA and 0.5 mM glycine in PBS for 30 min. Next,
blocked samples were incubated with TRITC-conjugated phalloidin in blocking buffer for
15 min at ambient conditions. After washing three times with PBS, the cell-seeded
hydrogel samples were counter-stained with DAPI to image the cell nuclei. The stained
samples were imaged with an inverted fluorescent microscope (Nikon Eclipse Ti ε, Nikon,
Melville, NY).
To evaluate the biocompatibility potential of SerAte-II to hMSCs, assessment of
cellular viability was carried out using the DNA content. Human mesenchymal stem cells
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(hMSCs) were encapsulated in the SerAte II hydrogel in a basal medium at a density of
1×106 cells/mL. At time points (1, and 3 days), cell-laden hydrogels were washed with
serum-free DMEM followed by washing with PBS. Next, the samples were lysed with 10
mM Tris supplemented with 0.2% triton in PBS and then lysed samples were used for
measurement of DNA content using Quant-it PicoGreen as we previously described [184].
Cell-free hydrogel well plates were used as controls.
3.2.10 Cell viability assay. For the cell viability assay, the hydrogels were prepared and
cultured as described to culture the cells. Live/dead staining was conducted to evaluate the
cell viability of hMSCs encapsulated in the hydrogels by using Cell stain Double Staining
Kit (Dojindo Laboratories, Tokyo, Japan). At days 1 and 3 of culture, the cell-laden diskshape hydrogels were collected, washed with PBS, and incubated with serum-free medium
containing calcein-AM (2 µM) and propidium iodide (4 µM) for 15 minutes. Next, the live
and dead cells were imaged with an inverted fluorescent microscope (Nikon Eclipse Ti ε,
Nikon, Melville, NY).
3.3 Results
3.3.1 Extraction of sericin and synthesis of sericin urethane methacryloyl (SerAte).
Sericin was extracted from silk cocoons using the acid, citric acid method (See “Methods”
for details), which is shown to extract sericin protein (properties by citric acid). We
introduced methacryloyl groups onto the reactive hydroxyl groups of sericin to obtain three
sericin derivatives (SerAte-I, SerAte-II and SerAte-III) with different levels of
methacryloyl modification by varying feed ratios of IEM to sericin, as in Table 3.1. The
1

HNMR spectra of the extracted sericin and SeraAte are shown in Figure 3.2a. The spectra

showed that the modification of sericin by isocyanato ethyl methacryloyl groups are
successful onto sericin as the new chemical shift “a” (δ 1.9 ppm) was corresponding to the
75

methyl protons and the chemical shift “b” (δ 5.4 ppm and 5.7 ppm) was resulting from the
double bond protons. The modification degrees were calculated to be 24%, 31% and 40%
by comparing the area of the methacrylate vinyl proton peaks to the area of the protons
associated with the serine and glycine groups, 3.6–4.0 (Ser CH2 and Gly CH2), in the sericin
backbone [181].
3.3.2 Effect of methacryalion on the secondary structure of SerAte. Circular Dichroism
(CD) spectra of the extracted sericin in PBS are shown in figure 3.3. The figure shows the
spectral comparison between extracted sericin and the SerAte with different modifications
in aqueous solution at rt. The CD curve of sericin displays two shallow, negative bands
centered at 217 and 230 nm. These results indicate that the conformation of sericin is a coil
containing a small amount of the β-form. The presence of the β-form in sericin could be
due to high serine content [185].
No major differences or spectral shifts were observed between the spectra of the sericin
(dashed line) and SerAte (solid line). Thus, we concluded that the secondary structure of
sericin remained intact upon the modification and was not affected during the process.
3.3.3 Mechanical properties, biodegradability and biocompatibility
3.3.3.1 Gelation kinetics of SerAte. The effect of UV irradiation time on storage (G’) and
loss (G”) moduli of a 24, 30, 40 wt% SerAte precursor solutions are shown in Figure 3.3
a-c. The gelation time of the SerAte precursor solution (the time at which G’= G”) was 80,
120 and, 190 s, respectively. The SerAte-I-15 solution did not form a hydrogel upon UV
irradiation (data not shown). However, the wt% of SerAte-II and SerAte-III solutions
formed a gel (G’≥ G”) in aqueous solution with the presence of photoinitiator with UV
irradiation. Gelation time decreased steadily from 190±25 s to 90±30 s as the modification
% increased from 24% to 40%. Based on the results in figure 3.3, the 30 % modification
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of sericin was selected for methacrylation of the extracted sericin in subsequent
degradation and cell culture experiments.
3.3.3.2 The microstructure of SerAte Hydrogels. Scanning EM images of hydrogels with
24, 30, and 40 wt% SerAte after freeze-drying is shown in Figure 3.4a-d. The crosslinked
SerAte hydrogels showed stable, interconnected, highly porous morphology with <5 µm
thick walls. At least 20 pores were selected from each SEM image of the freeze-dried
hydrogel samples to determine the mean and standard deviation of the pore sizes. The pore
size of the SerAte hydrogels decreased from 54±16 µm to 28±14 µm and 21±10 µm as the
concentration of SerAte-II in the precursor solution increased from 15 wt% to 17.5 % and
20 %, respectively. Compared to other hydrogels, x and y gels had significantly bigger pore
sizes. This may be the fact that x and y gels could adsorb more water. After lyophilization,
the space water occupied resulted in the formation of pores [186].
3.3.3.3 Compressive Modulus and Swelling Ratios of SerAte Hydrogels. Figures 3.2df show the effect of SerAte concentration in the precursor solution on swelling ratio in
aqueous solution, sol fraction, and compressive modulus of the hydrogels crosslinked with
high-intensity Omni Cure UV system. The compressive modulus of the hydrogels
increased from 1.8±0.3 to 7.7±0.4 kPa with increasing SerAte concentration from 10 to 25
wt% (Figure 3.3b), respectively, whereas the swelling ratio in PBS decreased from
390±40% to 150±25% and sol fraction decreased from 12±3% to 7±2%.
3.3.3.4 Thermal Stability of SerAte. The thermogravimetric analysis graph of the
extracted sericin (round dots) and SerAte after methacrylation (solid line) are shown in
Figure 3.3c. Thermal degradation of the extracted sericin and SerAte commenced at 230°C
and ended at 400°C resulting in a 64 % mass loss. There was not a significant difference
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between the thermographs of the extracted sericin and SerAte. Analysis of the TGA results
indicated that SerAte was thermally more stable than sericin because there was a
statistically significant difference (p<0.05) between mass losses of SerAte and sericin with
increasing temperature. Sericin and SerAte hydrogels underwent three stages of thermal
degradation including dehydration, depolymerization, and decomposition (Figure 3.3c).
The first stage was from room temperature to around 110 °C, where the mass loss revealed
the removal of adsorbed water molecules in sericin and SerAte hydrogels. The second
major decomposition was attributed to the degradation of sericin and SerAte occurred in
the temperature range of 120–410 °C. At this stage, the mass loss of sericin hydrogel was
faster than that of serAte, indicating that SerAte could improve the thermal stability of the
sericin and delay the thermal degradation process. At the last stage, the mass loss occurred
from 420 °C to 600 °C, which was associated with the breakdown of sericin and SerAte
[186].
The lyophilized SerAtes were highly porous (Figure 3.5). The pore sizes, porosity,
equilibrium weight swelling ratios, and degradation rates (in PBS at 37oC) of these
hydrogels were negatively correlated with methacrylation degrees (Table and Figure.),
while SerAtes’ stiffness was positively correlated with methacrylation degrees
(compressive moduli were 4 kPa for SerAte-I, 15 kPa for SerAte-II, and 36 kPa for SerAteIII). These correlations were likely attributed to different crosslinking densities resulting
from different levels of methacrylation across these hydrogels, which provides a practical
way of adjusting these physical and chemical properties to meet diverse therapeutic
requirements.”
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3.3.4 Cell Adhesion and Proliferation. The ability of sericin to promote cell attachment
is one of the key biological properties that are focused on this research. Human MSCs are
well known to adhere and proliferate on TCP, and therefore TCP was used as a control in
comparison to the SerAte-II. Figures 5a-d show the attachment of hMSCs on 2D SerAteII hydrogel at day1 and day3. At the initial attachment period day1, the number of cells
attached to the TCP and SerAte hydrogel was the same.
3.4 Discussion
Silk-sericin has been increasingly used in tissue engineering with various forms of
cell delivery systems, such as films, scaffolds and hydrogels due to its excellent
biocompatibility, biodegradability and valuable bioactivities [174, 175]. Silk industry is
the major source of sericin that produces as a by-product of around 50K tons annually.
However, such sericin was degraded (sericindegraded) because of the harshness extraction
method used in the degumming process. The sericindegraded was hard to crosslinked in the
form of hydrogels to be used in tissue engineering applications [176]. Instead, sericindegraded
was used to form cross-linkable, composite hydrogels with other polymers by biotoxic
crosslinkers leading to losing some of the sericin’s natural bioactivities [176]. To maintain
sericin’s natural properties and forming hydrogels, an aqueous solution of 1.25% of citric
acid was used to extract sericin from the cocoon. The yield percent of sericin based on the
weight of the feather was 35%. Citric acid is used to hydrolytically degum sericin from
fibroin under acidic conditions [187]. Urea treatment step was not included since extraction
with urea has a significant impact on sericin conformation [182]. The extracted sericin
obtained through the citric acid extraction method has two clearly different bands in SDSPAGE at the molecular weights (MW), approximately 85 kDa, and 100 kDa. These bands
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were closely consistent with the previously reported value of approximately 60 kDa, 100
kDa, and 130 kDa [174]. In contrast, SerAte-II has a less intense band at the molecular
weight 85 kDa, a wide range of molecular weights above 85 kDa and below 250 kDa that
is probably related to the multiple modifications of sericin by IEM [188]. As an alternative
hydrogel, a new chemical functionalization approach to an acid extracted sericin hydrogel
for tissue engineering by a photo-crosslinking method. By introducing ethyl methacryloyl
groups to sericin, sericin ethyl methacryloyl (SerAte) have successfully synthesized as a
hydrogel precursor for photo-crosslinking. Sericin modification with IEM and its gelation
method had an advantage over other sericin scaffolds. The network density and porous
structures of SerAtes were tuned simply by altering SerAtes methacrylation degrees that
controlled degradation rates and drug release kinetics.
The microstructure of SerAte hydrogels with different modifications showed
20−100 μm range of internal pore size with high porosity and pore interconnectivity.
Having high degrees of porosity and pore interconnectivity had a critical role in cells and
substance penetration, homogenous cell distribution, promote cell-cell interactions,
nutrients and metabolites transfer, and tissue growth. For instance, matrices with large pore
sizes between 115 to 335 μm were suitable for the formation of cartilaginous tissue. while,
matrices with small pore sizes were appropriate for chondrocyte phenotypes [189, 190].
The swelling ratio is another essential factor for the development of hydrogels in
therapeutic applications. Many studies have revealed that increased hydrogels’ porosity
and interconnectivity can improve the rate of swelling of the hydrogels because of
increasing the contact area between the hydrogels and media [173, 191]. Further, the
enlarge in porosity and interconnectivity could lead to a decrease in the solid content of the
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hydrogels, and result in a lower storage modulus [192]. In our result, the swelling ratio of
SerAte-I, II and II hydrogels were absorbing water from 1.5 up to 2.25-fold their initial
weight, showing that the hydrogels exhibited hydrophilic properties similar to tissue
environment and the capability to uptake cell culture medium. From the stability test, no
weight loss was observed from both hydrogels during 21 days, indicating that they could
support the entire cell culture experiments and were suitable for tissue engineering
applications.
These results of cell adhesion confirmed that SerAte hydrogel does facilitate cell
attachment, even though there were no cell adhesion sequences such as RGD and YIGSR
present in the protein. At day3, there were significantly more cells attached to the SerAte
as compared to TCP. Previous studies that were focusing on B. Mori sericin reported that
it supports fibroblasts adhesion and proliferation. It has been reported that the serine-rich
repetitive sequences found in sericin are responsible for the cell attachment activity [193].
Next, the grafting of sericin with methacrylate groups did not result in a significant
decrease in cell proliferation activity, and sericin-MA coatings from both species showed
a higher number of attached cells compared to the TCP control (Figure 3.5). Although it
was hypothesized that the functionalization process might denature or degrade the sericin
peptides, hence poses a negative effect on the bioactivity, it was not reflected in this [181].
3.5 Conclusion
A photo-polymerizable urethane methacrylate sericin (SerAte) was prepared
from sericin extracted from silk cocoon and used as a hydrogel for mesenchymal stem cells
immobilization. Human MSCs seeded on SerAte hydrogel had elongated spindle-shape
morphology compared to tissue culture plate TCP. Human MSCs seeded on SerAte
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hydrogels showed a similar rate of proliferation as those seeded on TCP. Further, the
mechanical properties, the network density and porous structures of SerAtes were tunable
simply by controlling Sericin’s methacrylation degrees covering the range of the
mechanical properties of various native tissues. Based on these results, this urethane
methacrylated sericin extracted from the cocoon is highly effective biopolymer,
biomimetic scaffold for encapsulation and delivery of stem cells to regenerate 3D artificial
tissue.
The short outcomes of collagen-based hydrogels in tissue engineering
applications are poor mechanical stability and poor durability prior to the secretion of
natural ECM proteins by the cells to resist matrix degradation [176, 184]. Gelatin and
gelatin derivatives show good solubility only in hot solutions, which might impact the
procedure of gelation and cell encapsulation [176]. Stable silk sericin biomaterials, such as
films, sponges, and hydrogels, are prepared by cross-linking, ethanol precipitation, or
blending with other polymers [175]. For instance, Films (2D) and scaffolds (3D) have been
obtained by blending SS with gelatin or glycogen and cross-linking with glutaraldehyde.
Both matrices were biocompatible, and SS promoted the attachment and proliferation of
feline fibroblasts in the 3D scaffolds but became toxic at concentrations of 5 and 7.5 wt%.
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Table 3.1 Percent degree of urethane methacrylation of Sericin when reacting with various
molar ratio of IEM
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Figure 3.1: Schematic diagram of sericin extraction and modification. (a,b) sericin was extracted from silk cocoons into an aqueous
solution containing citric acid. (c) The hydroxyl group of serine residues in sericin was converted to urethane methacrylate(d).
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Figure 3.2. (a) 1H NMR spectra of Sericin and SerAte with 24%, 31%, and 40% degree of
modification. (b) Spectra of sericin and SerAte in the range of 500-4000 cm-1.
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Figure 3.3 (a) SDS-PAGE from left to right for SerAte, Sericin, and standard protein MW
markers. (b) CD spectra of 0.1 mg/mL Sericin and SerAte in PBS with 24%, 31%, and 40%
degree of modification.
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Figure 3.4 (a-c) Effect of UV exposure time on storage (G’) and loss (G”) moduli of 20 wt% SerAte precursor solution (G’=G’’ at
gelation time) with photoinitiator. (d) Effect of SerAte concentration on the hydrogel compressive modulus. (e) TGA thermograms of
the extracted sericin (black curve) and modified sericin (SerAte, gray curve) (f) The stability of the hydrogels. The weight loss was
observed over time. Swelling ratios of the hydrogels after gelation and immersion into PBS. The weight change due to water absorption
was monitored over time. (g) Permeability of the hydrogels in term of molecular retention using dye retention study. (h) The values
expressed are means ± SD, n = 3
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Figure 3.5. SEM images of freeze-dried SerAte precursor solution after UV crosslinking
with SerAte II concentrations of 15 (a), 17.5 (b) and (c) 20 wt% (scale bar in a-d is 50 µm).
(d) presents si(e &f) show the fibrous structure of SerAte (scale bar is 5um and 1um).

Figure 3.6. DAPI (blue) and phalloidin (red) stained images of hMSCs seeded on TCP (a),
as a control, and SerAte II with 15, 17.5, and 20 wt% (b-d) hydrogels after 3 incubation in
basal medium, respectively (scale bar in a-d is 100 μm).
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Figure 3.7 (a and b) Live (green) and dead (red) stained images of hMSCs encapsulated in
20 wt % SerAte II hydrogels after zero- and 3-days incubation. (c and d) Trichrome
staining for the detection of extracellular collagen for encapsulated hMSCs in SerAte II.
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CHAPTER 4: SUMMARY OF FINDINGS AND FUTURE STUDIES
The results of the research presented in this dissertation show that the on-demand
release of rhBMP2 from plasmin cleavable NPs in the patterned constructs in response to
proteolytic factors like plasmin, MMPs, and tPA as well as others secreted by the
encapsulated cells led to highest extent of osteogenesis and vasculogenesis and coupling
of paracrine signaling between the differentiating hMSCs and ECFCs. This was
accomplished by three main studies.
The first study investigated that hMSCs and ECFCs encapsulated in a patterned
composite hydrogel release proteolytic factors like MMPs, plasminogen and tPA as well
as others and that the released factors are able to cleave plasmin-degradable peptides
embedded in NPs to release morphogens like rhBMP2 on-demand. The mRNA expressions
of uPA, tPA, and plasminogen in the fibrinolytic cascade for the LPELA encapsulated
MSCs, GelMA encapsulated ECFCs, and GelMA encapsulated MSCs + ECFCs with
incubation time. The encapsulated hMSCs expressed significant levels of uPA, tPA,
plasminogen, MMP2 and MT-MMP1 in osteogenic medium. The encapsulated ECFCs did
not express significant levels of proteases of the fibrinolytic cascade and the expressions
did not change with differentiation in a vasculogenic medium. The encapsulated hMSCs +
ECFCs expressed significant levels of tPA and plasminogen with differentiation in
vasculogenic medium. At the protein level for all cells, the extra- and intra-cellular
expressions of plasmin and MMP2 for the encapsulated hMSCs, ECFCs, and
hMSCs+ECFCs increased with cell differentiation.
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Based on the results in first study, where the encapsulated hMSCs showed higher
expression of proteases with differentiation in osteogenic medium as compared to ECFCs
or hMSCs+ECFCs in vasculogenic medium. The next study investigated the design of a
peptide-PEG macromer composed of a phenylalanine sequence for self-assembly and a
plasmin-cleavable sequence for BMP2 release in response to plasmin secretion by MSCs
and ECFCs. The PxSPCP NPs had a core-corona morphology with the self-assembling
peptides in the core and PEGs in the corona. The stability of NPs in aqueous solution and
the BMP2 stability against denaturation was a strong function of PEG MW. The P2SPCP
NPs with PEG MW of 2 kDa showed the most stable particle size distribution and protein
secondary structure with incubation.
The last study investigated the release characteristics, the bioactivity of the released
BMP2, and osteogenic and vasculogenic differentiation of hMSCs and ECFCs in patterned
hydrogels with plasmin-cleavable BMP2-P2SPCP NPs. The BMP2 grafted to P2SPCP NPs
and co-encapsulated in LPELA hydrogel with plasmin was gradually released to the
medium with incubation time at a rate faster than the non-cleavable BMP2-PxSP NPs but
slower than the free BMP2. Further, the released BMP2 from the NPs by the action of
plasmin induced differentiation of hMSCs encapsulated in the LPELA hydrogel. Human
MSCs and BMP2-PxSPCP NPs were encapsulated in the matrix whereas hMSCs+ECFCs
and VEGF-NGs were encapsulated in the microchannels of the patterned construct. Our
results showed that the hMSC/ECFC co-culture results in patterned constructs demonstrate
that the on-demand release of BMP2 from plasmin-cleavable PxSPCP NPs enhanced
osteogenesis and vasculogenesis compared to the direct addition of BMP2.
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